AU2018311981A1 - Methods for treating active eosinophilic esophagitis - Google Patents
Methods for treating active eosinophilic esophagitis Download PDFInfo
- Publication number
- AU2018311981A1 AU2018311981A1 AU2018311981A AU2018311981A AU2018311981A1 AU 2018311981 A1 AU2018311981 A1 AU 2018311981A1 AU 2018311981 A AU2018311981 A AU 2018311981A AU 2018311981 A AU2018311981 A AU 2018311981A AU 2018311981 A1 AU2018311981 A1 AU 2018311981A1
- Authority
- AU
- Australia
- Prior art keywords
- patient
- pathway inhibitor
- eoe
- inhibitor
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000000708 eosinophilic esophagitis Diseases 0.000 title claims abstract description 207
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 title claims abstract description 198
- 238000000034 method Methods 0.000 title claims abstract description 165
- 239000003112 inhibitor Substances 0.000 claims abstract description 189
- 102000003816 Interleukin-13 Human genes 0.000 claims abstract description 183
- 108090000176 Interleukin-13 Proteins 0.000 claims abstract description 183
- 102000004388 Interleukin-4 Human genes 0.000 claims abstract description 168
- 108090000978 Interleukin-4 Proteins 0.000 claims abstract description 168
- 230000037361 pathway Effects 0.000 claims abstract description 150
- 102000002171 Interleukin-4/interleukin-13 Human genes 0.000 claims abstract description 6
- 108050009538 Interleukin-4/interleukin-13 Proteins 0.000 claims abstract description 6
- 210000003979 eosinophil Anatomy 0.000 claims description 76
- 229950003468 dupilumab Drugs 0.000 claims description 73
- 208000019505 Deglutition disease Diseases 0.000 claims description 68
- 210000003238 esophagus Anatomy 0.000 claims description 64
- 238000011282 treatment Methods 0.000 claims description 54
- 239000000427 antigen Substances 0.000 claims description 53
- 108091007433 antigens Proteins 0.000 claims description 53
- 102000036639 antigens Human genes 0.000 claims description 53
- 239000012634 fragment Substances 0.000 claims description 51
- 239000008194 pharmaceutical composition Substances 0.000 claims description 50
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims description 41
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 41
- 210000002966 serum Anatomy 0.000 claims description 35
- 239000000090 biomarker Substances 0.000 claims description 34
- 239000013566 allergen Substances 0.000 claims description 33
- 201000010099 disease Diseases 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 31
- 230000010339 dilation Effects 0.000 claims description 28
- 230000002327 eosinophilic effect Effects 0.000 claims description 27
- 208000024891 symptom Diseases 0.000 claims description 27
- 239000003246 corticosteroid Substances 0.000 claims description 26
- 230000000694 effects Effects 0.000 claims description 23
- 235000013305 food Nutrition 0.000 claims description 23
- 230000009467 reduction Effects 0.000 claims description 22
- 102100021935 C-C motif chemokine 26 Human genes 0.000 claims description 21
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 21
- 230000008595 infiltration Effects 0.000 claims description 20
- 238000001764 infiltration Methods 0.000 claims description 20
- 238000002560 therapeutic procedure Methods 0.000 claims description 20
- 108010083698 Chemokine CCL26 Proteins 0.000 claims description 19
- 102100023698 C-C motif chemokine 17 Human genes 0.000 claims description 16
- 108010082169 Chemokine CCL17 Proteins 0.000 claims description 16
- 102000013888 Eosinophil-Derived Neurotoxin Human genes 0.000 claims description 16
- 108010050456 Eosinophil-Derived Neurotoxin Proteins 0.000 claims description 16
- 206010020751 Hypersensitivity Diseases 0.000 claims description 16
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims description 16
- 108010029307 thymic stromal lymphopoietin Proteins 0.000 claims description 16
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 14
- 235000020932 food allergy Nutrition 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 206010016946 Food allergy Diseases 0.000 claims description 13
- 108010002616 Interleukin-5 Proteins 0.000 claims description 13
- 208000006673 asthma Diseases 0.000 claims description 13
- 230000006872 improvement Effects 0.000 claims description 13
- 229940126409 proton pump inhibitor Drugs 0.000 claims description 13
- 239000000612 proton pump inhibitor Substances 0.000 claims description 13
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 12
- 201000010105 allergic rhinitis Diseases 0.000 claims description 12
- 229960001334 corticosteroids Drugs 0.000 claims description 12
- 206010061218 Inflammation Diseases 0.000 claims description 11
- 102100037765 Periostin Human genes 0.000 claims description 11
- 101710199268 Periostin Proteins 0.000 claims description 11
- 230000004054 inflammatory process Effects 0.000 claims description 11
- 238000012986 modification Methods 0.000 claims description 11
- 230000004048 modification Effects 0.000 claims description 11
- 230000009885 systemic effect Effects 0.000 claims description 11
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 10
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 10
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 10
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 10
- 201000008937 atopic dermatitis Diseases 0.000 claims description 10
- 235000005911 diet Nutrition 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 208000030961 allergic reaction Diseases 0.000 claims description 9
- 230000037213 diet Effects 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 125000002091 cationic group Chemical group 0.000 claims description 8
- 239000013568 food allergen Substances 0.000 claims description 8
- 239000000523 sample Substances 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 206010047700 Vomiting Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 239000000428 dust Substances 0.000 claims description 7
- 238000003384 imaging method Methods 0.000 claims description 7
- 230000008673 vomiting Effects 0.000 claims description 7
- 206010067171 Regurgitation Diseases 0.000 claims description 6
- -1 serum ECP Proteins 0.000 claims description 6
- 208000004998 Abdominal Pain Diseases 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 5
- 230000008719 thickening Effects 0.000 claims description 5
- 241000251468 Actinopterygii Species 0.000 claims description 4
- 244000105624 Arachis hypogaea Species 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- 235000021307 Triticum Nutrition 0.000 claims description 4
- 241000209140 Triticum Species 0.000 claims description 4
- 235000013365 dairy product Nutrition 0.000 claims description 4
- 235000013601 eggs Nutrition 0.000 claims description 4
- 235000019688 fish Nutrition 0.000 claims description 4
- 235000014571 nuts Nutrition 0.000 claims description 4
- 229940124624 oral corticosteroid Drugs 0.000 claims description 4
- 235000020232 peanut Nutrition 0.000 claims description 4
- 235000015170 shellfish Nutrition 0.000 claims description 4
- 229940125379 topical corticosteroid Drugs 0.000 claims description 4
- 230000004580 weight loss Effects 0.000 claims description 4
- 244000099147 Ananas comosus Species 0.000 claims description 3
- 235000007119 Ananas comosus Nutrition 0.000 claims description 3
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 3
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 3
- 235000018262 Arachis monticola Nutrition 0.000 claims description 3
- 235000007319 Avena orientalis Nutrition 0.000 claims description 3
- 235000007558 Avena sp Nutrition 0.000 claims description 3
- 241000282326 Felis catus Species 0.000 claims description 3
- 241000287828 Gallus gallus Species 0.000 claims description 3
- 241000238631 Hexapoda Species 0.000 claims description 3
- 240000005979 Hordeum vulgare Species 0.000 claims description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 3
- 102000013691 Interleukin-17 Human genes 0.000 claims description 3
- 102000000585 Interleukin-9 Human genes 0.000 claims description 3
- 108010002335 Interleukin-9 Proteins 0.000 claims description 3
- 235000011430 Malus pumila Nutrition 0.000 claims description 3
- 235000015103 Malus silvestris Nutrition 0.000 claims description 3
- 235000015278 beef Nutrition 0.000 claims description 3
- 235000013330 chicken meat Nutrition 0.000 claims description 3
- 244000013123 dwarf bean Species 0.000 claims description 3
- 239000003862 glucocorticoid Substances 0.000 claims description 3
- 235000021331 green beans Nutrition 0.000 claims description 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 3
- 230000001861 immunosuppressant effect Effects 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 235000015277 pork Nutrition 0.000 claims description 3
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 claims description 3
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 claims description 3
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 3
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 2
- 241000581835 Monodora junodii Species 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 102100039897 Interleukin-5 Human genes 0.000 claims 3
- 241000209763 Avena sativa Species 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 206010061958 Food Intolerance Diseases 0.000 claims 1
- 241000009328 Perro Species 0.000 claims 1
- 229940089918 ansaid Drugs 0.000 claims 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 15
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 230000008859 change Effects 0.000 description 72
- 239000000902 placebo Substances 0.000 description 41
- 229940068196 placebo Drugs 0.000 description 41
- 238000012216 screening Methods 0.000 description 41
- 150000001413 amino acids Chemical group 0.000 description 39
- 238000007920 subcutaneous administration Methods 0.000 description 21
- 229940079593 drug Drugs 0.000 description 18
- 238000001839 endoscopy Methods 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 18
- 230000003442 weekly effect Effects 0.000 description 17
- 208000031481 Pathologic Constriction Diseases 0.000 description 16
- 238000001574 biopsy Methods 0.000 description 14
- 210000000416 exudates and transudate Anatomy 0.000 description 14
- 206010030113 Oedema Diseases 0.000 description 13
- 208000026935 allergic disease Diseases 0.000 description 12
- 230000002378 acidificating effect Effects 0.000 description 11
- 230000007935 neutral effect Effects 0.000 description 11
- 230000009747 swallowing Effects 0.000 description 11
- 208000007217 Esophageal Stenosis Diseases 0.000 description 10
- 102000000743 Interleukin-5 Human genes 0.000 description 10
- 206010030194 Oesophageal stenosis Diseases 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 238000002483 medication Methods 0.000 description 9
- 210000004877 mucosa Anatomy 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 238000012384 transportation and delivery Methods 0.000 description 9
- 230000000172 allergic effect Effects 0.000 description 8
- 208000010668 atopic eczema Diseases 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 210000004602 germ cell Anatomy 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 206010000269 abscess Diseases 0.000 description 6
- 230000007815 allergy Effects 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 6
- 230000002962 histologic effect Effects 0.000 description 6
- 206010020718 hyperplasia Diseases 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 210000004400 mucous membrane Anatomy 0.000 description 6
- 208000012657 Atopic disease Diseases 0.000 description 5
- 206010008479 Chest Pain Diseases 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102000025171 antigen binding proteins Human genes 0.000 description 5
- 108091000831 antigen binding proteins Proteins 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 210000001723 extracellular space Anatomy 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000007634 remodeling Methods 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000003266 anti-allergic effect Effects 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 230000003628 erosive effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 3
- 206010014950 Eosinophilia Diseases 0.000 description 3
- 102100028314 Filaggrin Human genes 0.000 description 3
- 101710088660 Filaggrin Proteins 0.000 description 3
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 description 3
- 201000005505 Measles Diseases 0.000 description 3
- 208000005647 Mumps Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940125715 antihistaminic agent Drugs 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 235000004251 balanced diet Nutrition 0.000 description 3
- 208000018631 connective tissue disease Diseases 0.000 description 3
- 239000000850 decongestant Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 208000010805 mumps infectious disease Diseases 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229940127558 rescue medication Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 201000005404 rubella Diseases 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000011285 therapeutic regimen Methods 0.000 description 3
- 231100000611 venom Toxicity 0.000 description 3
- 102100026439 Adhesion G protein-coupled receptor E1 Human genes 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 244000075850 Avena orientalis Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 101000718225 Homo sapiens Adhesion G protein-coupled receptor E1 Proteins 0.000 description 2
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 206010038776 Retching Diseases 0.000 description 2
- 102000013968 STAT6 Transcription Factor Human genes 0.000 description 2
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 2
- 235000007238 Secale cereale Nutrition 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 230000009850 completed effect Effects 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 229940124581 decongestants Drugs 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 235000020883 elimination diet Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940125369 inhaled corticosteroids Drugs 0.000 description 2
- 239000002919 insect venom Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229960000470 omalizumab Drugs 0.000 description 2
- 229940127249 oral antibiotic Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000021055 solid food Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 1
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 102100022511 Cadherin-like protein 26 Human genes 0.000 description 1
- 102100025871 Calpain-14 Human genes 0.000 description 1
- 101710165502 Calpain-14 Proteins 0.000 description 1
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000000289 Esophageal Achalasia Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 1
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 1
- 101000899450 Homo sapiens Cadherin-like protein 26 Proteins 0.000 description 1
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101001123334 Homo sapiens Proteoglycan 3 Proteins 0.000 description 1
- 101000863884 Homo sapiens Sialic acid-binding Ig-like lectin 8 Proteins 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 208000034264 Hypermobile Ehlers-Danlos syndrome Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010022061 Injection site erythema Diseases 0.000 description 1
- 102100020941 Interleukin-4 Human genes 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- 208000005137 Joint instability Diseases 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010024570 Lip swelling Diseases 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 201000005978 Loeys-Dietz syndrome Diseases 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 206010063569 Metastatic squamous cell carcinoma Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 101100477560 Mus musculus Siglec5 gene Proteins 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030136 Oesophageal achalasia Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010058522 Oesophageal injury Diseases 0.000 description 1
- 206010064342 Oesophageal oedema Diseases 0.000 description 1
- 206010030210 Oesophageal varices haemorrhage Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100028964 Proteoglycan 3 Human genes 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 102100029964 Sialic acid-binding Ig-like lectin 8 Human genes 0.000 description 1
- 206010042727 Swollen tongue Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 206010047482 Viral upper respiratory tract infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 201000000621 achalasia Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000013567 aeroallergen Substances 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 235000003484 annual ragweed Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 201000009089 atopic dermatitis 5 Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 235000006263 bur ragweed Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 235000003488 common ragweed Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000002674 endoscopic surgery Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 208000024170 esophageal varices Diseases 0.000 description 1
- 201000010120 esophageal varix Diseases 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229940091348 latex Drugs 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 108010010907 pitrakinra Proteins 0.000 description 1
- 229950008185 pitrakinra Drugs 0.000 description 1
- 238000013439 planning Methods 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 239000013573 pollen allergen Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 235000009736 ragweed Nutrition 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 208000020352 skin basal cell carcinoma Diseases 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention provides methods for treating, preventing or reducing the severity of active eosinophilic esophagitis. In certain embodiments, the present invention provides methods of increasing esophageal distensibility. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4/ interleukin-13 (IL-4/IL-13) pathway inhibitor such as an anti-IL-4R antibody.
Description
METHODS FOR TREATING ACTIVE EOSINOPHILIC ESOPHAGITIS [0001] This application is being filed on August 3, 2018 as a PCT International Patent Application and claims the benefit of priority to US Provisional Patent Application Nos. 62/541,242, filed on August 4, 2017; 62/561,593, filed on September 21, 2017; and European Application No. EP18305252.1, filed March 8, 2018, the disclosures of each herein incorporated by reference in their entireties.
FIELD OF THE INVENTION [0002] The present invention relates to the use of interleukin-4/ interleukin-13 pathway inhibitors to treat or prevent active eosinophilic esophagitis in a subject in need thereof.
BACKGROUND [0003] Esophageal stricture (narrowing of the esophagus) results from injury to the esophageal lining and leads to, inter alia, difficulty in swallowing (dysphagia), regurgitation of food or liquid, heartbum and unintended weight loss. Treatment of esophageal stricture is very important as it reduces quality of life due to dysphagia, weight loss, and nutritional imbalance. Esophageal stricture may be caused due to chronic ulceration or chronic inflammation, as a complication due to chemotherapy, radiotherapy, esophageal cancer or endoscopic surgery, peptic ulcers or gastroesophageal reflux. Esophageal stricture is also caused by eosinophilic esophagitis.
[0004] Eosinophilic esophagitis (EoE) is an emerging, chronic, immune-/antigenmediated disease characterized by esophageal dysfunction and eosinophil inflammation in the esophagus (Liacouras et al 2011, The Journal of Allergy and Clinical Immunology. 128: 3-20 e6; quiz 1-2; Weinbrand-Goichberg et al 2013, Immunologic Research. 56: 24960; Zhang et al 2013, Digestive Diseases and Sciences 58: 1497-506). Adult patients with EoE have substantially impaired quality of life (QOL) due to dysphagia and the possible risk of food impaction (DeBrosse et al 2011, The Journal of Allergy and Clinical Immunology 128: 132-8; Falk et al 2014, Gastroenterology Clinics of North America 43: 231-42; Straumann 2008, Gastrointestinal Endoscopy Clinics of North America 18: 99118; Straumann et al 2003, Gastroenterology 125: 1660-9). Patients with active disease or with moderate-to-severe EoE suffer from esophageal stricture leading to difficulty in swallowing, regurgitation of food or liquid and weight loss. Emergency endoscopy for prolonged food impactions is associated with a risk of severe esophageal injury. EoE is
WO 2019/028367
PCT/US2018/045195 found to be associated with food allergy in many patients. Some patients may also have concomitant asthma or an atopic disease such as atopic dermatitis, or allergic rhinitis. The symptomatic burden of EoE, including food avoidance, eating modification behaviors, and social, emotional, financial, work and school, and sleep impacts, is also important and relevant to the EoE population and, if improved, may reflect a treatment benefit for EoE patients.
[0005] Current therapeutic approaches include chronic dietary elimination (including food allergen withdrawal), swallowed topical formulation corticosteroids (not approved for the treatment of EoE in the US), and esophageal dilation. Although swallowed topical corticosteroids have been reported in clinical trials to induce partial clinical responses and histologic remission, they are not uniformly effective and can be associated with fungal infections as well as disease recurrence after discontinuation. There are currently no approved drug therapies for EoE. Thus, an unmet need exists in the art for effective therapeutic approaches without adverse side effects that prevent or treat eosinophilic esophagitis. Esophageal stricture may be treated with proton pump inhibitors, which inhibit gastric acid secretion. Esophageal dilation by endoscopy is currently used to treat esophageal stricture and increase esophageal distensibility. However, it is a surgical procedure that is invasive and may lead to complications such as perforation and bleeding. Accordingly, there is an unmet need for safe and effective therapies that increase esophageal distensibility and treat esophageal stricture (e.g., in eosinophilic esophagitis).
BRIEF SUMMARY OF THE INVENTION [0006] According to one aspect of the present invention, methods are provided for increasing the distensibility of the esophagus. The methods, according to this aspect, comprise: (a) selecting a patient with moderate-to-severe eosinophilic esophagitis (EoE), wherein the patient in need thereof has an attribute or is selected on the basis of a criterion selected from the group consisting of: (i) the patient has >15 eosinophils per high powered field (hpf) in the esophagus prior to or at the time of the treatment (“baseline”);
(ii) the patient exhibits at least one episode of dysphagia per week; and (iii) the patient has a Straumann Dysphagia Instrument (SDI) score >2; and (b) administering a therapeutically effective amount of a pharmaceutical composition comprising an interleukin-4/ interleukin-13 (IL-4/IL-13) pathway inhibitor to the patient in need thereof, thereby increasing esophageal distensibility, as measured by a functional lumen imaging probe (EndoFLIP®, Crospon, Ireland). In one embodiment, the patient has active EoE. In one
WO 2019/028367
PCT/US2018/045195 embodiment, the patient is >18 years of age. In one embodiment, the patient has been treated previously with proton pump inhibitors (PPIs). In one embodiment, the patient has had at least one prior esophageal dilation. In one embodiment, the patient has a characteristic selected from the group consisting of: (1) prior treatment with at least one of PPIs, esophageal dilation, corticosteroids, allergen withdrawal and/or diet modification;
(2) the patient is unresponsive or resistant to prior treatment with PPIs or esophageal dilation; (3) the patient has an Eosinophilic Esophagitis Severity and Activity Index (EEsAI) score >30, >40, or >50; (4) the patient suffers from EoE for at least 3 years; (5) the patient, prior to or at the time of administration of the IL-4/IL-13 pathway inhibitor, has or is diagnosed with a disease or disorder selected from the group consisting of food allergy, atopic dermatitis, asthma, allergic rhinitis and allergic conjunctivitis; and (6) the patient has an elevated level of a biomarker selected from the group consisting of eotaxin3, periostin, serum IgE (total and allergen-specific), IL-13, IL-5, serum thymus and activation regulated chemokine (TARC), thymic stromal lymphopoietin (TSLP), serum eosinophilic cationic protein (ECP), and eosinophil-derived neurotoxin (EDN). [0007] In embodiments of the invention that specify the selection of “at least one... selected from the group consisting of’ or simply “selected from the group consisting of’, the use of the conjunction “and/or” between the final two items of the list following such language indicates that the items in the sequence are alternatives to one another, and that one (or more) of these items is/are selected. It does not mean that each of the items is necessarily selected. For example, for a method of increasing esophageal distensibility, wherein the patient has at least one characteristic selected from the group consisting of:
(1) prior treatment with at least one of PPIs, esophageal dilation, corticosteroids, allergen withdrawal, and/or diet modification;
(2) the patient is unresponsive or resistant to prior treatment with PPIs or esophageal dilation;
(3) the patient has an Eosinophilic Esophagitis Severity and Activity Index (EEsAI) score >30, >40, or >50;
(4) the patient has suffered from EoE for at least 3 years;
(5) the patient, prior to or at the time of administration of the IL-4/IL-13 pathway inhibitor, has or is diagnosed with a disease or disorder selected from the group consisting of food allergy, atopic dermatitis, asthma, allergic rhinitis, and/or allergic conjunctivitis; and/or
WO 2019/028367
PCT/US2018/045195 (6) the patient has an elevated level of at least one biomarker selected from the group consisting of eotaxin-3, periostin, serum IgE (total and allergen-specific), IL-13, IL-5, serum thymus and activation regulated chemokine (TARC), thymic stromal lymphopoietin (TSLP), serum eosinophilic cationic protein (ECP), and/or eosinophil-derived neurotoxin (EDN), what is meant is that the patient has at least characteristic (1) or characteristic (2) or characteristic (3) or characteristic (4) or characteristic (5) or characteristic (6). The patient can also, based on such language, have more than one of the six characteristics (for example, (1) and (2), or (4) and (5), or (1), (2), and (6), and so on). It is not, however, meant that the patient must have at least characteristic (1) and characteristic (2) and characteristic (3) and characteristic (4) and characteristic (5) and characteristic (6).
[0008] According to another aspect of the present invention, methods are provided for treating, preventing or ameliorating at least one symptom or indication of active eosinophilic esophagitis (EoE) in a subject. The methods, according to this aspect of the invention, comprise selecting a patient with moderate-to-severe EoE, and administering a therapeutically effective amount of a pharmaceutical composition comprising an interleukin-4/ interleukin-13 (IL-4/IL-13) pathway inhibitor to the patient in need thereof. In certain embodiments, the patient in need thereof is selected on the basis of an attribute or criterion selected from the group consisting of: (1) the patient has >15 eosinophils per high powered field (hpf) in the esophagus prior to or at the time of the treatment (“baseline”); (2) prior treatment with at least one of high dose proton pump inhibitors (PPIs), esophageal dilation, corticosteroids, allergen withdrawal and/or diet modification;
(3) the patient exhibits at least one episode of dysphagia per week; (4) the patient is unresponsive or resistant to prior treatment with high dose PPIs or esophageal dilation; (5) the patient has a Straumann Dysphagia Instrument (SDI) score >5; (6) the patient has an Eosinophilic Esophagitis Severity and Activity Index (EEsAI) score >30, >40, or >50; (7) the patient suffers from EoE for at least 3 years; (8) the patient, prior to or at the time of administration of the IL-4/IL-13 pathway inhibitor, has or is diagnosed with a disease or disorder selected from the group consisting of food allergy, atopic dermatitis, asthma, allergic rhinitis and allergic conjunctivitis; and (9) the patient has an elevated level of a biomarker selected from the group consisting of eotaxin-3, periostin, serum IgE (total and allergen-specific), IL-13, IL-5, serum thymus and activation regulated chemokine (TARC), thymic stromal lymphopoietin (TSLP), serum eosinophilic cationic protein (ECP), and eosinophil-derived neurotoxin (EDN).
WO 2019/028367
PCT/US2018/045195 [0009] According to another aspect of the present invention, methods are provided for reducing dysphagia, the methods comprising selecting a patient with moderate-to-severe EoE wherein the patient (i) exhibits >1 episodes of dysphagia per week; (ii) has been treated previously with high-dose proton pump inhibitors (PPIs); and/or (iii) has had at least one prior esophageal dilation; and (b) administering a therapeutically effective amount of a pharmaceutical composition comprising an IL-4/IL-13 pathway inhibitor to the patient in need thereof.
[0010] According to another aspect of the present invention, methods are provided for improving a parameter, the methods comprising selecting a patient with moderate-tosevere EoE; and administering a therapeutically effective amount of a pharmaceutical composition comprising an IL-4/IL-13 pathway inhibitor, wherein the administration leads to an improvement in a parameter selected from the group consisting of: (a) reduction of at least 40% from baseline in dysphagia frequency and severity, as measured by Straumann Dysphagia Instrument (SDI) score; (b) reduction of 3 points from baseline in the SDI score; (c) reduction of more than 85% from baseline in peak intraepithelial eosinophil count in proximal, mid and/or distal regions of the esophagus; (d) increase of at least 10% from baseline in esophageal distensibility, as measured by impedance planimetry; (e) decrease of more than 50% from baseline in severity and extent of disease, as measured by EoE Histology Scoring System (HSS) score; and (f) reduction of more than 30% from baseline in dysphagia, as measured by Eosinophilic Esophagitis Severity and Activity Index (EEsAI) score.
[0011] According to another aspect of the present invention, methods are provided for reducing the eosinophilic infiltration of esophagus in a patient in need thereof. In certain embodiments, methods are provided for reducing inflammation in the esophagus. The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising an IL-4/IL-13 pathway inhibitor. In certain embodiments, the eosinophilic infiltration of the esophagus is represented by greater than or equal to about 15 eosinophils per high powered field in the esophagus of the subject in need thereof. In certain embodiments, the number of eosinophils is reduced >85% following administration of the IL-4/IL-13 pathway inhibitor. In certain embodiments, the inflammation (e.g., mucosal inflammation) is identified by endoscopy and features such as esophageal edema, rings, exudates, furrows and strictures (EREFS). In certain embodiments, administration of the IL-4/IL-13 pathway inhibitor leads to reduction in the EREFS score to less than 8,
WO 2019/028367
PCT/US2018/045195 less than 7, less than 6, less than 5, less than 4, less than 3, or less than 2 (disclosed elsewhere herein).
[0012] According to another aspect of the present invention, methods are provided for reducing the level of an EoE-associated biomarker in a subject. In certain embodiments, the EoE-associated biomarker is selected from the group consisting of, e.g., circulating or esophagus eosinophils, eotaxin-3, periostin, serum IgE (total and allergen-specific), IL-13, IL-5, serum thymus and activation regulated chemokine (TARC; CCL17), thymic stromal lymphopoietin (TSLP), serum eosinophilic cationic protein (ECP), and eosinophil-derived neurotoxin (EDN). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising an IL-4/IL-13 pathway inhibitor. [0013] In certain embodiments, the IL-4/IL-13 pathway inhibitor is administered in combination with a second therapeutic agent or therapy.
[0014] In certain embodiments, the subject in need thereof has a concurrent disease or disorder selected from the group consisting of food allergy, atopic dermatitis, asthma, allergic rhinitis, allergic conjunctivitis and inherited connective tissue disorders.
[0015] Exemplary IL-4/IL-13 pathway inhibitors that can be used in the context of the methods of the present invention include, but are not limited to, an anti-IL-4 antibody, an anti-IL-13 antibody, a bispecific anti-IL-4/IL-13 antibody and an IL-4 receptor (IL-4R) inhibitor. In one embodiment, the IL-4/IL-13 pathway inhibitor is an IL-4R inhibitor (such as an anti-IL-4R antibody).
[0016] Exemplary IL-4R inhibitors that can be used in the context of the methods of the present invention include, e.g., small molecule chemical inhibitors of IL-4R or its ligands (IL-4 and/or IL-13), or biological agents that target IL-4R or its ligands. According to certain embodiments, the IL-4R inhibitor is an antibody or antigen-binding protein that binds the IL-4Ra chain and blocks signaling by IL-4, IL-13, or both IL-4 and IL-13. In certain embodiments, the anti-IL-4R antibody or antigen-binding protein comprises the heavy chain complementarity determining regions (HCDRs) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 1 and the light chain CDRs of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 2. One such type of antigen-binding protein that can be used in the context of the methods of the present invention is an anti-IL-4Ra antibody such as dupilumab. [0017] In certain embodiments, the present invention provides use of an IL-4/IL-13 pathway inhibitor in the manufacture of a medicament to treat or inhibit or prevent active eosinophilic esophagitis in a subject, including humans.
WO 2019/028367
PCT/US2018/045195 [0018] In certain embodiments, the present invention provides use of an antibody or antigen-binding fragment thereof that binds to IL-4R in the manufacture of a medicament to treat or inhibit or prevent active eosinophilic esophagitis in a subject, including humans. [0019] In certain embodiments, the present invention provides use of an IL-4/IL-13 pathway inhibitor in the manufacture of a medicament to increase esophageal distensibility in a subject, including humans. In one embodiment, the subject has active EoE. In one embodiment, the subject has moderate-to-severe EoE.
[0020] In certain embodiments, the present invention provides use of an antibody or antigen-binding fragment thereof that binds to IL-4R in the manufacture of a medicament to increase esophageal distensibility in a subject, including humans. In one embodiment, the subject has active EoE. In one embodiment, the subject has moderate-to-severe EoE [0021] Other embodiments of the present invention will become apparent from a review of the ensuing detailed description.
BRIEF DESCRIPTION OF THE FIGURES [0022] Figure 1 lists the components comprising the weekly Eosinophilic Esophagitis Severity and Activity Index (EEsAI) score.
[0023] Figure 2 shows mean change from baseline in Straumann Dysphagia Instrument (SDI) scores during the 12-week treatment period in patients administered once-a-week (qw) 300 mg dupilumab vs placebo.
[0024] Figure 3 shows mean percent change from baseline in dysphagia frequency and severity components of the Straumann Dysphagia Instrument (SDI) score at week 10 and week 12 upon administration of once-a-week (qw) 300 mg dupilumab vs placebo.
[0025] Figure 4 shows the mean percent change from baseline in EEsAI score during the 12-week treatment period in patients administered once-a-week (qw) 300 mg dupilumab vs placebo.
[0026] Figure 5 shows mean percent change from baseline in total EoE Edema Rings Exudates Furrows and Strictures (EREFS) score as well as in the subcomponents of the EREFS score at week 12 in patients administered once-a-week (qw) 300 mg dupilumab vs placebo.
[0027] Figure 6 shows mean change from baseline in total EoE Histology Scoring System (HSS) score for the grade (severity) subcomponent at week 12 in patients administered once-a-week (qw) 300 mg dupilumab vs placebo.
WO 2019/028367
PCT/US2018/045195 [0028] Figure 7 shows mean change from baseline in total EoE HSS score for the stage (extent) subcomponent at week 12 in patients administered once-a-week (qw) 300 mg dupilumab vs placebo.
[0029] Figure 8 is made up of Figures 8A, 8B, 8C, and 8D. Figure 8A shows mean change from baseline in EoE HSS grade scores for basal zone hyperplasia; Figure 8B shows mean change from baseline in EoE HSS grade scores for eosinophil surface layering; Figure 8C shows mean change from baseline in EoE HSS grade scores for eosinophil inflammation; and Figure 8D shows mean change from baseline in EoE HSS grade scores for eosinophil abscess in proximal, mid and distal regions of the esophagus sampled at week 12 from patients administered once-a-week (qw) 300 mg dupilumab vs placebo.
[0030] Figure 9 is made up of Figures 9A, 9B, 9C, and 9D. Figure 9A shows mean change from baseline in EoE HSS stage scores for basal zone hyperplasia; Figure 9B shows mean change from baseline in EoE HSS stage scores for eosinophil abscess; Figure 9C shows mean change from baseline in EoE HSS stage scores for eosinophil inflammation; and Figure 9D shows mean change from baseline in EoE HSS stage scores for eosinophil surface layering in proximal, mid and distal regions of the esophagus sampled at week 12 from patients administered once-a-week (qw) 300 mg dupilumab vs placebo.
[0031] Figure 10 is made up of Figures 10A, 10B, and 10C. Figure 10A shows mean change from baseline in EoE HSS grade scores for dilated intercellular spaces; Figure 10B shows mean change from baseline in EoE HSS grade scores for surface alteration and Figure 10C shows mean change from baseline in EoE HSS grade scores for apoptotic epithelial cells in proximal, mid and distal regions of the esophagus sampled at week 12 from patients administered once-a-week (qw) 300 mg dupilumab vs placebo.
[0032] Figure 11 is made up of Figures 11 A, 11B, and 11C. Figure HA shows mean change from baseline in EoE HSS stage scores for dilated intercellular spaces; Figure 11B shows mean change from baseline in EoE HSS stage scores for surface alteration and Figure 11C shows mean change from baseline in EoE HSS stage scores for apoptotic epithelial cells in proximal, mid and distal regions of the esophagus sampled at week 12 from patients administered once-a-week (qw) 300 mg dupilumab vs placebo.
[0033] Figure 12 shows percent change from baseline in distensibility plateau at week 12 in patients administered once-a-week (qw) 300 mg dupilumab vs placebo.
WO 2019/028367
PCT/US2018/045195
DETAILED DESCRIPTION [0034] Before the present invention is described, it is to be understood that this invention is not limited to particular methods and experimental conditions described, as such methods and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
[0035] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. As used herein, the term “about,” when used in reference to a particular recited numerical value, means that the value may vary from the recited value by no more than 1%. For example, as used herein, the expression “about 100” includes 99 and 101 and all values in between (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0036] Although any methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to describe in their entirety.
Methods for Treating, Preventing or Ameliorating Eosinophilic Esophagitis [0037] The present invention includes methods for treating, preventing, or ameliorating at least one symptom or indication of active eosinophilic esophagitis (EoE) in a subject. The methods according to this aspect of the invention comprise administering a therapeutically effective amount of a pharmaceutical composition comprising an IL-4/IL13 pathway inhibitor to the subject in need thereof. As used herein, the terms “treat”, “treating”, or the like, mean to alleviate symptoms, eliminate the causation of symptoms either on a temporary or permanent basis, or to prevent or slow the appearance of symptoms of eosinophilic inflammation in the esophagus. In certain embodiments, the present methods are useful for treating or ameliorating at least one symptom or indication of EoE including, but not limited to, eosinophilic infiltration of the esophagus, thickening of the esophageal wall, inflammation in the esophagus, appearance of trachea-like rings or ridges in the esophagus, chest and abdominal pain, food refusal, vomiting, dysphagia and food impaction.
[0038] “Eosinophilic Esophagitis” (EoE), as used herein, means an inflammatory disease characterized by abnormal eosinophilic inflammation within the esophagus and esophageal dysfunction. The primary symptoms of EoE include, but are not limited to,
WO 2019/028367
PCT/US2018/045195 chest and abdominal pain, dysphagia, heartbum, food refusal, vomiting and food impaction. The clinicopathology of EoE is characterized by presence of ridges or trachealike rings in the esophageal wall and eosinophilic infiltration in the esophageal mucosa. EoE is diagnosed by endoscopy of the esophagus followed by microscopic and biochemical analysis of the esophageal mucosal lining. EoE may be classified as allergic or non-allergic depending upon the status of the subject. The present invention includes methods to treat both allergic and non-allergic forms of EoE.
[0039] As used herein, the term “active EoE” refers to the EoE disease in a patient wherein the patient has >15 eosinophils/high powered field (hpf) in an esophageal biopsy even after 8 weeks of treatment with proton pump inhibitors (PPIs). The term also refers to the EoE disease in patients that exhibit frequent dysphagia, e.g., the patient has 2, 3, 4, 5, or more episodes of dysphagia per week. The term “active EoE” includes mild EoE as well as moderate-to-severe EoE. The term “moderate-to-severe” refers to EoE disease in patients that in addition to eosinophilia (e.g.., >15 eosinophils/hpf in the esophageal mucosa) and frequent episodes of dysphagia, have SDI score >2 and/or EEsAI score >30, have duration of EoE for at least 2 years, and/or are non-responsive or resistant to prior therapy (including PPIs or esophageal dilation).
[0040] As used herein, the expression “a subject in need thereof’ means a human or nonhuman mammal that exhibits one or more symptoms or indications of eosinophilic esophagitis, and/or who has been diagnosed with eosinophilic esophagitis (EoE). Throughout the present disclosure, the term “subject” is used interchangeably with the term “patient”. The term “a subject in need thereof’ may also include, e.g, patients who, prior to treatment, exhibit (or have exhibited) one or more indications of EoE such as, e.g, esophageal overexpression of pro-inflammatory mediators such as mast cells, eosinophilic infiltration of the esophagus, thickening of the esophageal wall, dysphagia, food impaction and chest and abdominal pain and/or an elevated level of a EoE-associated biomarker. The term specifically includes subjects who show the presence of > 15 eosinophils per high power field in the esophagus. In certain embodiments, the term also includes subjects with elevated peripheral eosinophil counts (e.g, >100, >150, >200, or >300 cells/μΐ) or elevated serum IgE (>150kU/L).
[0041] In certain embodiments, the present methods may be used to treat patients who exhibit pathology and symptoms that are observed in subjects with chronic esophagitis including in gastroesophageal reflux disease (GERD). In certain embodiments, the term “a subject in need thereof’ includes subjects that are non-responsive to or resistant to anti
WO 2019/028367
PCT/US2018/045195
GERD therapy. For example, the present methods may be used to treat subjects that are resistant to proton pump inhibitors (PPI).
[0042] In the context of the present invention, “a subject in need thereof’ may include a subset of population that is more susceptible to EoE or may show an elevated level of an EoE-associated biomarker. For example, “a subject in need thereof’ may include a subject suffering from an atopic disease or disorder such as food allergy, atopic dermatitis, asthma, allergic rhinitis and allergic conjunctivitis. In certain embodiments, the term “a subject in need thereof’ includes a patient who, prior to or at the time of administration of the IL-4/IL-13 pathway inhibitor, has or is diagnosed with a disease or disorder selected from the group consisting of food allergy, atopic dermatitis, asthma, allergic rhinitis and allergic conjunctivitis. In certain embodiments, the term “a subject in need thereof’ may include patients with inherited connective tissue disorders. Such a subject population may show an elevated level of an EoE-associated biomarker such as, e.g., IgE, eotaxin-3, periostin, IL-5, or IL-13.
[0043] In certain embodiments, “a subject in need thereof’ includes a patient susceptible to an allergen. For example, “a subject in need thereof’ includes a patient who may exhibit one of the following characteristics: (a) is prone to allergic reactions or responses when exposed to one or more allergens; (b) has previously exhibited an allergic response or reaction to one or more allergens; (c) has a known history of allergies; and/or (d) exhibits a sign or symptom of an allergic response or anaphylaxis. In certain embodiments, the patient is allergic to an allergen associated with EoE or that renders the subject susceptible and/or prone to developing EoE.
[0044] The term “allergen,” as used herein, includes any substance, chemical, particle or composition that is capable of stimulating an allergic response in a susceptible individual. Allergens may be contained within or derived from a food item such as, e.g, dairy products (e.g, cow's milk), egg, wheat, soy, com, rye, fish, shellfish, peanuts and tree nuts. Alternatively, an allergen may be contained within or derived from a non-food item such as, e.g, dust (e.g., containing dust mite), pollen, insect venom (e.g, venom of bees, wasps, mosquitoes, etc.), mold, animal dander, latex, medication, drugs, ragweed, grass and birch.
[0045] In certain embodiments, the term “a subject in need thereof’ includes a subset of population that exhibits an allergic reaction to a food allergen. For example, “a subject in need thereof’ may include a subject who has an allergy to an allergen contained in a food item including, but not limited to, a dairy product, egg, wheat, soy, com, rye, fish,
WO 2019/028367
PCT/US2018/045195 shellfish, peanut, a tree nut, beef, chicken, oat, barley, pork, green beans, and fruits such as apple and pineapple.
[0046] In certain embodiments, the term includes a subject allergic to a non-food allergen such as allergens derived from dust, mold, insects, plants including pollen, and pets such as cats and dogs. Examples of non-food allergens (also known as environmental allergens or aeroallergens) include, but are not limited to, house dust mite allergens, pollen allergens, animal dander allergens, insect venom, grass allergens, and latex.
[0047] As used herein, the phrases “allergic response,” “allergic reaction,” “allergic symptom,” and the like, include one or more signs or symptoms selected from the group consisting of urticaria (e.g., hives), angioedema, rhinitis, asthma, vomiting, sneezing, runny nose, sinus inflammation, watery eyes, wheezing, bronchospasm, reduced peak expiratory flow (PEF), gastrointestinal distress, flushing, swollen lips, swollen tongue, reduced blood pressure, anaphylaxis, and organ dysfunction/failure. An “allergic response,” “allergic reaction,” “allergic symptom,” etc., also includes immunological responses and reactions such as, e.g, increased IgE production, increased allergen-specific immunoglobulin production and/or eosinophilia.
[0048] In some embodiments, the methods herein are for the treatment of adults, adolescents or children. An adult is >18 years of age, an adolescent is >12 and <18 years of age and children are < 12 years of age. In some embodiments, the methods herein may be used to treat EoE in children who are < 3 years old. In one embodiment, an inhibitor of the IL-4/IL-13 pathway is used to treat moderate-to severe EoE in subjects that are not adequately controlled with standard-of-care treatment (e.g, oral corticosteroids, dilation, etc.) The subject can be an adult, an adolescent or a child.
[0049] The present invention also includes methods to increase esophageal distensibility. The methods according to this aspect of the invention comprise administering to the patient in need thereof one or more doses of a pharmaceutical composition comprising an IL-4/IL-13 pathway inhibitor, thereby increasing the distensibility of the esophagus in the patient.
[0050] The present invention also includes methods for reducing eosinophilic infiltration. The methods according to this aspect of the invention comprise administering to the patient in need thereof one or more doses of a pharmaceutical composition comprising an IL-4/IL-13 pathway inhibitor to reduce or eliminate the number of eosinophils, e.g, in the esophageal mucosa.
WO 2019/028367
PCT/US2018/045195 [0051] As used herein, “eosinophilic infiltration” refers to the presence of eosinophils in an organ or tissue including blood, esophagus, stomach, duodenum, and ileum of a subject. In the context of the invention, the term “eosinophilic infiltration” refers to presence of eosinophils in the mucosal lining of a region of the gastro-intestinal tract including, but not limited to, esophagus and stomach. Eosinophilic infiltration is analyzed, for example, in an esophageal tissue biopsy of a subject suffering from EoE. According to particular embodiments, “eosinophilic infiltration” refers to the presence of > 15 eosinophils per high power field in the esophagus. The term “high power field” refers to a standard total magnification of 400X by a microscope used to view eosinophils in a tissue, e.g., from the esophagus of a subject. In certain embodiments, “eosinophilic infiltration” includes infiltration into a tissue by leucocytes, for example, lymphocytes, neutrophils and mast cells. The leucocyte infiltration into, e.g, esophageal tissue can be detected by cell surface markers such as eosinophil-specific markers (e.g., CDllcLow/Neg, SiglecF+, F4/80+, EMR1+, Siglec 8+, and MBP2+), macrophage-specific markers (e.g., CDllb+, F4/80+, CD14+, EMR1+, and CD68+), neutrophil-specific markers (e.g., CDllb+, Ly6G+, Ly6C+, CDllb+, and CD66b+), and T-cell-specific markers (e.g., CD3+CD4+ CD8+).
[0052] As used herein, a reduction in esophagus eosinophils means that the number of eosinophils and other leucocytes measured in the esophagus of a subject with EoE and who has been treated with an IL-4/IL-13 pathway inhibitor, is at least 5%, 10%, 20%, 50%, 70%, 80%, or 90% lower than the esophagus eosinophils measured in the same or an equivalent subject that has not been treated with the IL-4/IL-13 pathway inhibitor. In certain embodiments, reducing eosinophilic infiltration means detecting less than 15 eosinophils per high power field, more preferably less than 10 eosinophils, less than 9 eosinophils, less than 8 eosinophils, less than 7 eosinophils, less than 6 eosinophils, or less than 5 eosinophils per high power field in a biopsy of the esophageal mucosa. In certain embodiments, a reduction in esophagus eosinophils means that no eosinophils are detected in the esophageal mucosa of a subject.
[0053] The present invention includes methods for treating, preventing or reducing the severity of eosinophilic esophagitis comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an IL-4/IL-13 pathway inhibitor to a subject in need thereof, wherein the pharmaceutical composition is administered to the subject in multiple doses, e.g., as part of a specific therapeutic dosing regimen. For example, the therapeutic dosing regimen may comprise administering multiple doses of the pharmaceutical composition to the subject at a frequency of about once a day, once
WO 2019/028367
PCT/US2018/045195 every two days, once every three days, once every four days, once every five days, once every six days, once a week, once every two weeks, once every three weeks, once every four weeks, once a month, once every two months, once every three months, once every four months, or less frequently.
[0054] The methods of the present invention, according to certain embodiments, comprise administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising an IL-4/IL-13 pathway inhibitor in combination with a second therapeutic agent. The second therapeutic agent may be an agent selected from the group consisting of, e.g., an IL-lbeta inhibitor, an IL-5 inhibitor, an IL-9 inhibitor, an IL-13 inhibitor, an IL-17 inhibitor, an IL-25 inhibitor, a TNFalpha inhibitor, an eotaxin-3 inhibitor, an IgE inhibitor, a prostaglandin D2 inhibitor, an immunosuppressant, a topical corticosteroid, an oral corticosteroid (e.g., budesonide), a systemic corticosteroid, an inhaled corticosteroid, a glucocorticoid, a proton pump inhibitor, a decongestant, an antihistamine, and anon-steroidal anti-inflammatory drug (NSAID). In certain embodiments, the IL-4/IL-13 pathway inhibitor of the invention may be administered in combination with therapy including esophagus dilation, allergen removal and diet management. As used herein, the phrase ‘in combination with” means that the pharmaceutical composition comprising an IL-4/IL-13 pathway inhibitor is administered to the subject at the same time as, just before, or just after administration of the second therapeutic agent. In certain embodiments, the second therapeutic agent is administered as a co-formulation with the IL-4/IL-13 pathway inhibitor. In a related embodiment, the present invention includes methods comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an IL-4/IL-13 pathway inhibitor to a subject who is on a background anti-allergy therapeutic regimen. The background antiallergy therapeutic regimen may comprise a course of administration of, e.g, steroids, antihistamines, decongestants, anti-IgE agents, etc. The IL-4/IL-13 pathway inhibitor (e.g, an anti-IL-4R antibody) may be added on top of the background anti-allergy therapeutic regimen. In some embodiments, the IL-4/IL-13 pathway inhibitor is added as part of a “background step-down” scheme, wherein the background anti-allergy therapy is gradually withdrawn from the subject over time (e.g, in a stepwise fashion) while the IL4/IL-13 pathway inhibitor is administered the subject at a constant dose, or at an increasing dose, or at a decreasing dose, over time. In certain embodiments, the IL-4/IL-13 pathway inhibitor is administered as a monotherapy.
WO 2019/028367
PCT/US2018/045195
Eosinophilic Esophagitis-associated Biomarkers [0055] The present invention also includes methods involving the use, quantification, and analysis of EoE-associated biomarkers. As used herein, the term “EoE-associated biomarker” means any biological response, cell type, parameter, protein, polypeptide, enzyme, enzyme activity, metabolite, nucleic acid, carbohydrate, or other biomolecule which is present or detectable in an EoE patient at a level or amount that is different from (e.g., greater than or less than) the level or amount of the marker present or detectable in a non-EoE patient. Exemplary EoE-associated biomarkers include, but are not limited to, e.g, esophagus eosinophils, eotaxin-3 (CCL26), periostin, serum IgE (total and allergenspecific), serum IgG (total and allergen-specific), IL-13, IL-5, serum thymus and activation regulated chemokine (TARC; CCL17), thymic stromal lymphopoietin (TSLP), serum eosinophilic cationic protein (ECP), calpain 14, filaggrin (FLG), signal transducer and activator of transcription 6 (STAT6), interleukin 4 receptor (IL-4R), and eosinophilderived neurotoxin (EDN). The term “EoE-associated biomarker” also includes a gene or gene probe known in the art that is differentially expressed in a subject with EoE as compared to a subject without EoE. For example, genes which are significantly upregulated in a subject with EoE include, but are not limited to, T-helper 2 (Th2)-associated chemokines such as CCL8, CCL23 and CCL26, periostin, cadherin-like-26, and TNFainduced protein 6 (Blanchard et al 2006, J. Clin. Invest. 116: 536 - 547). Alternatively, “EoE-associated biomarker” also includes genes that are down regulated due to EoE such as terminal differentiation proteins (e.g, filaggrin) (Blanchard et al 2006, J. Clin. Invest. 116: 536 - 547). Certain embodiments of the invention relate to use of these biomarkers for monitoring disease reversal with the administration of the IL-4/IL-13 pathway inhibitor. Methods for detecting and/or quantifying such EoE-associated biomarkers are known in the art; kits for measuring such EoE-associated biomarkers are available from various commercial sources; and various commercial diagnostic laboratories offer services which provide measurements of such biomarkers as well.
[0056] According to certain aspects of the invention, methods for treating EoE are provided which comprise: (a) selecting a subject who exhibits a level of at least one EoEassociated biomarker prior to or at the time of treatment which signifies the disease state; and (b) administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an IL-4/IL-13 pathway inhibitor. In certain embodiments of this aspect of the invention, the subject is selected on the basis of an elevated level of IgE or eotaxin-3.
WO 2019/028367
PCT/US2018/045195 [0057] According to other aspects of the invention, methods for treating EoE are provided which comprise administering to a subject a pharmaceutical composition comprising a therapeutically effective amount of an IL-4/IL-13 pathway inhibitor, wherein administration of the pharmaceutical composition to the subject results in a decrease in at least one EoE-associated biomarker (e.g., esophagus eosinophils, eotaxin-3, IgE, etc.) at a time after administration of the pharmaceutical composition, as compared to the level of the biomarker in the subject prior to the administration.
[0058] As will be appreciated by a person of ordinary skill in the art, an increase or decrease in an EoE-associated biomarker can be determined by comparing (i) the level of the biomarker measured in a subject at a defined time point after administration of the pharmaceutical composition comprising an IL-4/IL-13 pathway inhibitor to (ii) the level of the biomarker measured in the patient prior to the administration of the pharmaceutical composition comprising an IL-4/IL-13 pathway inhibitor (i.e., the “baseline measurement”). The defined time point at which the biomarker is measured can be, e.g., at about 4 hours, 8 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 15 days, 20 days, 35 days, 40 days, 50 days, 55 days, 60 days, 65 days, 70 days, 75 days, 80 days, 85 days, or more after administration of the of the pharmaceutical composition comprising an IL-4/IL-13 pathway inhibitor.
[0059] According to certain embodiments of the present invention, a subject may exhibit a decrease in the level of one or more of IgE and/or eotaxin-3 following administration of a pharmaceutical composition comprising an IL-4/IL-13 pathway inhibitor (e.g, an antiIL-4R antibody). For example, at about day 1, day 4, day 8, day 15, day 22, day 25, day 29, day 36, day 43, day 50, day 57, day 64, day 71 or day 85, following administration of a first, second, third or fourth dose of a pharmaceutical composition comprising about 75 mg to about 600 mg of an anti-IL-4R antibody (e.g, dupilumab), the subject, according to the present invention, may exhibit a decrease in eotaxin-3 of about 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more from baseline (wherein “baseline” is defined as the level of eotaxin-3 in the subject just prior to the first administration). Similarly, at about day 1, day 4, day 8, day 15, day 22, day 25, day 29, day 36, day 43, day 50, day 57, day 64, day 71 or day 85, following administration of a first, second, third or fourth dose of a pharmaceutical composition comprising about 75 mg to about 600 mg of an anti-IL-4R antibody (e.g., dupilumab), the subject, according to the present invention, may exhibit a decrease in IgE of about 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%,
WO 2019/028367
PCT/US2018/045195
65%, 70%, 75%, 80%, 85%, 90%, 95% or more from baseline (wherein “baseline” is defined as the level of IgE in the subject just prior to the first administration).
[0060] The present invention also includes methods for determining whether a subject is a suitable subject for whom administration of a pharmaceutical composition comprising an IL-4/IL-13 pathway antagonist would be beneficial. For example, if an individual, prior to receiving a pharmaceutical composition comprising an IL-4/IL-13 pathway antagonist, exhibits a level of an EoE-associated biomarker that signifies the disease state, the individual is therefore identified as a suitable patient for whom administration of a pharmaceutical composition of the invention (a composition comprising an anti-IL-4R antibody) would be beneficial. In related embodiments, the present invention includes methods for treating suitable subjects, wherein a suitable subject may be more susceptible to EoE, for example, due to food allergy, or an atopic disease. For example, the present invention includes methods comprising administering an IL-4/IL-13 pathway antagonist to subjects who have food allergy, atopic dermatitis, asthma, allergic rhinitis or allergic conjunctivitis. In another example, the present invention includes methods comprising administering an IL-4/IL-13 pathway antagonist to subjects who have, Mendelianinherited connective tissue disorders, e.g., Marfan syndrome, Loeys-Dietz syndrome, hypermobile Ehlers Danlos syndrome (EDS) or joint hypermobility syndrome (JHS). Such subject populations may have an elevated level of an EoE-associated biomarker.
[0061] According to certain exemplary embodiments, an individual may be identified as a good candidate for anti-IL-4/IL-13 therapy if the individual exhibits one or more of the following: (i) an eotaxin-3 level greater than about 30 pg/ml, greater than about 40 pg/ml, greater than about 50 pg/ml, greater than about 100 pg/ml, greater than about 1500 pg/ml, greater than about 200 pg/ml, greater than about 250 pg/ml, greater than about 300 pg/ml, greater than about 350 pg/ml, greater than about 400 pg/ml, greater than about 450 pg/ml, or greater than about 500 pg/ml; or (ii) a serum IgE level greater than about 114 kU/L, greater than about 150 kU/L, greater than about 500 kU/L, greater than about 1000 kU/L, greater than about 1500 kU/L, greater than about 2000 kU/L, greater than about 2500 kU/L, greater than about 3000 kU/L, greater than about 3500 kU/L, greater than about 4000 kU/L, greater than about 4500 kU/L, or greater than about 5000 kU/L; or (iii) >15 eosinophils per high power field in the esophagus of the subject. Additional criteria, such as other clinical indicators of EoE (e.g., dysphagia, thickening of the esophageal wall, and food allergy indicative of EoE), may be used in combination with any of the foregoing
WO 2019/028367
PCT/US2018/045195
EoE-associated biomarkers to identify an individual as a suitable candidate for anti-IL4/IL-13 therapy as described elsewhere herein.
Eosinophilic esophagitis-related parameters [0062] The present invention includes methods for improving one or more eosinophilic esophagitis (EoE)-related parameters in a subject in need thereof, wherein the methods comprise administering a pharmaceutical composition comprising an IL-4/IL-13 pathway inhibitor to the subject.
[0063] Examples of EoE-related parameters include: (a) Straumann Dysphagia Instrument (SDI); (b) Eosinophilic Esophagitis Activity Index (EEsAI); (c) Eosinophilic Esophagitis Edema Rings Exudates Furrows and Strictures (EoE-EREFS); (d) Eosinophilic Esophagitis Histological Scoring System (EoE-HSS) (e) Esophageal intraepithelial eosinophils; and (f) Esophageal distensibility. An improvement in an EoErelated parameter means a decrease from baseline of one or more of SDI, EEsAI, EoEEREFS, EoE-HSS, or esophageal intraepithelial eosinophils. An improvement in esophageal distensibility means an increase from the baseline. As used herein, the term baseline, with regard to an EoE-related parameter, means the numerical value of the EoE-related parameter for a subject prior to or at the time of administration of a pharmaceutical composition of the present invention.
[0064] To determine whether an EoE-related parameter has improved, the parameter is quantified at baseline and at one or more time-points after administration of the pharmaceutical composition of the present invention. For example, an EoE-related parameter may be measured at day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10, day 11, day 12, day 14, day 15, day 22, day 25, day 29, day 36, day 43, day 50, day 57, day 64, day 71, day 85; or at the end of week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10, week 11, week 12, week 13, week 14, week 15, week 16, week 17, week 18, week 19, week 20, week 21, week 22, week 23, week 24, or longer, after the initial treatment with a pharmaceutical composition of the present invention. The difference between the value of the parameter at a particular time point following initiation of treatment and the value of the parameter at baseline is used to establish whether there has been an improvement (e.g., a decrease) in the EoE-related parameter.
[0065] Straumann Dysphagia Instrument (SDI). The SDI is a non-validated patient reported outcome (PRO) that has been used in clinical studies to determine the frequency and intensity of dysphagia (Straumann 2010). The SDI has a 1-week recall period.
WO 2019/028367
PCT/US2018/045195
Frequency of dysphagia events is graded on a 5-point scale: 0 = none, 1 = once per week, 2 = several times per week, 3 = once per day, and 4 = several times per day, and intensity of dysphagia events is graded on a 6-point scale: 0 = swallowing unrestricted, 1 = slight sensation of resistance, 2 = slight retching with delayed passage, 3 = short period of obstruction necessitating intervention (e.g., drinking, breathing), 4 = longer-lasting period obstruction only removable by vomiting, and 5 = long-lasting complete obstruction requiring endoscopic intervention. The total SDI score ranges from 0 to 9. According to certain embodiments of the present invention, administration of an IL-4/IL-13 pathway inhibitor to a patient results in a decrease in SDI score of 3 points from the baseline. For example, the present invention includes therapeutic methods that result in a decrease from baseline in SDI score of decrease of 1, 2, 3, 4, 5, 6 or more points from baseline in SDI. In certain exemplary embodiments, administration of an IL-4/IL-13 pathway inhibitor to a patient results in a decrease at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, or more at day 4, 8, 15, 22, 25, 29, 36, 43, 50, 57, 64, 71, 85 or later following administration of the IL-4/IL-13 pathway inhibitor (e.g., following subcutaneous administration of about 300 mg of an anti-IL-4R antibody or antigen-binding fragment thereof). In certain exemplary embodiments of the present invention, administration of an IL-4/IL-13 pathway inhibitor to a subject results in a decrease from baseline in SDI of at least 40%.
[0066] Eosinophilic Esophagitis Activity Index (EEsAI). The EEsAI is a non-validated, multimodular index in development at University Hospital Inselspital (Berne, Switzerland) (Schoepfer 2014), a part of the international EEsAI study group. The EEsAI PRO module (questionnaire) used in this study includes items related to the intensity and frequency of dysphagia, the influence of specific food groups on dysphagia symptoms, and other symptoms independent of eating or drinking (i.e., heartbum, acid regurgitation, and chest pain). The total EEsAI PRO score ranges from 0 to 100 (Figure 1), wherein higher scores indicate worse symptoms. The score consists of 5 parts: frequency of trouble swallowing, duration of trouble swallowing, pain when swallowing, visual dysphagia question, and avoidance, modification and slow eating (AMS). According to certain embodiments of the present invention, administration of an IL-4/IL-13 pathway inhibitor to a patient results in a decrease in EEsAI score. For example, the present invention includes therapeutic methods which result in a decrease from baseline in EEsAI score of at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, or more at day 4, 8, 15, 22, 25, 29, 36, 43, 50, 57, 64, 71, 85 or later following administration of the IL-4/IL-13 pathway inhibitor (e.g,
WO 2019/028367
PCT/US2018/045195 following subcutaneous administration of about 300 mg of an anti-IL-4R antibody or antigen-binding fragment thereof). In certain exemplary embodiments of the present invention, administration of an IL-4/IL-13 pathway inhibitor to a subject results in a decrease from baseline in EEsAI score of at least 30% after administration.
[0067] Eosinophilic Esophagitis Edema Rings Exudates Furrows and Strictures (EoEEREFS). The EoE-EREFS (edema, rings, exudates, furrows, strictures) is used to measure the endoscopically identified EoE esophageal mucosal inflammatory and remodeling features. This instrument includes a total of 17 items related to the presence and severity of esophageal features. The specific esophageal features include: rings (concentric rings around esophagus - absent, mild, moderate, severe, not applicable); strictures (narrowing of the esophagus - yes, no, not applicable); diameter of the stricture (if applicable); exudates (refer to white plaques - absent, mild, severe), furrows (vertical lines down the esophagus - absent, present); edema (loss of vascular markings of the mucosa - absent, present); crepe paper esophagus (absent, present); overall general appearance incorporating all endoscopically identified EoE findings (i.e., fixed rings, strictures, whitish exudates, furrowing, edema, and crepe paper mucosa). In addition, mucosal changes associated with gastroesophageal reflux disease are recorded using the Los Angeles classification system for erosions (No Erosions or LA Classification A, B, C, D). The EoE esophageal characteristics are analyzed based on the EoE-EREFS, a validated scoring system for inflammatory and remodeling features of disease using both overall scores and scores for each individual characteristic (Hirano 2014). According to certain embodiments of the present invention, administration of an IL-4/IL-13 pathway inhibitor to a patient results in a decrease in EoE-EREFS score. For example, the present invention includes therapeutic methods which result in a decrease from baseline in EREFS score of at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75% or more at day 4, 8, 15, 22, 25, 29, 36, 43, 50, 57, 64, 71, 85 or later following administration of the IL-4/IL-13 pathway inhibitor (e.g., following subcutaneous administration of about 300 mg of an anti-IL-4R antibody or antigen-binding fragment thereof).
[0068] Eosinophilic Esophagitis Histological Scoring System (EoE-HSS). The EoEHSS generate separate severity (grade) and extent (stage) disease scores. The score is used to measure 8 histologic features (parameters) of EoE from 3 different regions (proximal, mid and distal) of the esophagus (Collins et al 2017). The 8 parameters include: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated
WO 2019/028367
PCT/US2018/045195 intercellular spaces, surface epithelial alteration, dyskeratotic cells, and lamina propria fibrosis. A scale of 0 - 3 is used for each parameter, both grade and stage (0 being least inflamed, normal). According to certain embodiments of the present invention, administration of an IL-4/IL-13 pathway inhibitor to a patient results in a decrease in EoEHSS score. For example, the present invention includes therapeutic methods which result in a decrease from baseline in EoE-HSS of at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75% or more at day 4, 8, 15, 22, 25, 29, 36, 43, 50, 57, 64, 71, 85 or later following administration of the IL-4/IL-13 pathway inhibitor (e.g., following subcutaneous administration of about 300 mg of an anti-IL-4R antibody or antigen-binding fragment thereof). In certain exemplary embodiments of the present invention, administration of an IL-4/IL-13 pathway inhibitor to a subject results in a decrease from baseline in EoE-HSS score of at least 50%.
[0069] Esophageal intraepithelial eosinophils. It refers to >15 eosinophils per high powered field (hpf) in esophageal biopsies. Peak intraepithelial eosinophils refers to >15 eosinophils per high powered field in at least 2 of 3 esophageal regions sampled. According to certain embodiments of the present invention, administration of an IL-4/IL13 pathway inhibitor to a patient results in a decrease in peak intraepithelial eosinophils. For example, the present invention includes therapeutic methods which result in a decrease from baseline in intraepithelial eosinophils of at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85% or more at day 4, 8, 15, 22, 25, 29, 36, 43, 50, 57, 64, 71, 85 or later following administration of the IL-4/IL-13 pathway inhibitor (e.g, following subcutaneous administration of about 300 mg of an antiIL-4R antibody or antigen-binding fragment thereof). In certain exemplary embodiments of the present invention, administration of an IL-4/IL-13 pathway inhibitor to a subject results in a decrease from baseline in intraepithelial eosinophils of at least 85%.
[0070] Esophageal Distensibilitv. Esophageal distensibility is assessed by using the endoluminal functional lumen imaging probe (EndoFLIP, Crospon, Ireland) to measure the diameter of the esophageal lumen and pressure. The EndoFLIP device is a catheter based procedure that measures the cross sectional area at multiple sites along the esophagus with simultaneous intraluminal pressure recordings during volumetric distension of the esophagus. The analyses of cross sectional area versus pressure relationships of the esophagus allow for determination of esophageal compliance as well as the distensibility plateau (DP). The DP has been shown to be significantly reduced in patients with EoE compared to healthy controls (Kwiatek 2011). According to certain
WO 2019/028367
PCT/US2018/045195 embodiments of the present invention, administration of an IL-4/IL-13 pathway inhibitor to a patient results in an increase in esophageal distensibility. For example, the present invention includes therapeutic methods which result in an increase from baseline in esophageal distensibility of at least about 5%, 10%, 15%, 20%, 25% or more at the end of week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or later following administration of the IL-4/IL-13 pathway inhibitor (e.g., following subcutaneous administration of about 300 mg of an antiIL-4R antibody or antigen-binding fragment thereof). In certain exemplary embodiments of the present invention, administration of an IL-4/IL-13 pathway inhibitor to a subject results in an increase from baseline in esophageal distensibility of at least 10%, as measured by impedance planimetry.
[0071] Adult Eosinophilic Esophagitis Quality of Life (EoE-QoL-A) Questionnaire. The EoE-QOL-A questionnaire is a validated disease-specific measure of health-related quality of life in EoE patients (Taft 2011). The instrument used in this study, the EoE-QOL-A v.3.0, includes 30 items related to established domains such as social functioning, emotional functioning, and disease impact of daily life experiences. The EoE-QOL-A has a 1-week recall period. The items are graded on a 5-point scale: ‘Not at All,’ ‘Slightly,’ ‘Moderately,’ ‘Quite a bit,’ and ‘Extremely’. According to certain embodiments, administration of an IL-4/IL-13 pathway inhibitor to a patient results in an increase in quality of life parameters in the patient.
IL-4/IL-13 Pathway Inhibitors [0072] The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an IL-4/IL-13 pathway inhibitor.
[0073] As used herein, an “IL-4/IL-13 pathway inhibitor” (also referred to herein as an “IL-4/IL-13 pathway antagonist,” an “IL-4/IL-13 pathway blocker,” etc.) is any agent that inhibits or attenuates at least one of: (i) the binding of IL-4 and/or IL-13 to their respective receptors; (ii) signaling and/or activity of IL-4 and/or IL-13; and/or (iii) the downstream signaling/activity that results from binding of IL-4 and/or IL-13 to their respective receptors. Exemplary IL-4/IL-13 pathway inhibitors include, but are not limited to, antiIL-4 antibodies (e.g, the antibodies disclosed in US Patent 7740843, and US Patent Application Publications 20100297110, 20160207995 ), anti-IL-13 antibodies (e.g, the antibodies disclosed in US Patents 7501121, 7674459, 7807788, 7910708, 7915388, 7935343, 8088618, 8691233, 9605065, US Patent Application Publications 20060073148, 20080044420, and EP2627673B1), bispecific antibodies that bind to IL-4 and IL-13 (e.g, the antibodies disclosed in US Patent 8388965, US Patent Application Publications
WO 2019/028367
PCT/US2018/045195
20110008345, 20130251718, 20160207995), and IL-4 receptor (IL-4R) inhibitors (described below).
[0074] As used herein, an “IL-4R inhibitor” (also referred to herein as an “IL-4/IL-13 pathway inhibitor,” an “IL-4Ra antagonist,” an “IL-4R blocker,” an “IL-4Ra blocker,” etc.) is any agent that binds to or interacts with IL-4Ra or an IL-4R ligand, and inhibits or attenuates the normal biological signaling function a type 1 and/or a type 2 IL-4 receptor. Human IL-4Ra has the amino acid sequence of SEQ ID NO: 11. A type 1 IL-4 receptor is a dimeric receptor comprising an IL-4Ra chain and a yc chain. A type 2 IL-4 receptor is a dimeric receptor comprising an IL-4Ra chain and an IL-13Ral chain. Type 1 IL-4 receptors interact with and are stimulated by IL-4, while type 2 IL-4 receptors interact with and are stimulated by both IL-4 and IL-13. Thus, the IL-4R inhibitors that can be used in the methods of the present invention may function by blocking IL-4-mediated signaling, IL-13-mediated signaling, or both IL-4- and IL-13-mediated signaling. The IL4R inhibitors of the present invention may thus prevent the interaction of IL-4 and/or IL13 with a type 1 or type 2 receptor.
[0075] Non-limiting examples of categories of IL-4R inhibitors include IL-4 muteins (e.g., pitrakinra), small molecule IL-4R inhibitors, anti-IL-4R aptamers, peptide-based IL4R inhibitors (e.g, “peptibody” molecules), “receptor-bodies” (e.g, engineered molecules comprising the ligand-binding domain of an IL-4R component), and antibodies or antigenbinding fragments of antibodies that specifically bind human IL-4Ra. As used herein, IL4R inhibitors also include antigen-binding proteins that specifically bind IL-4 and/or IL13.
Anti-IL-4Ra Antibodies and Antigen-Binding Fragments Thereof [0076] According to certain exemplary embodiments of the present invention, the IL4/IL-13 pathway inhibitor is an anti-IL-4Ra antibody or antigen-binding fragment thereof. The term “antibody,” as used herein, includes immunoglobulin molecules comprising four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds, as well as multimers thereof (e.g, IgM). In atypical antibody, each heavy chain comprises a heavy chain variable region (abbreviated herein as HCVR or Vh) and a heavy chain constant region. The heavy chain constant region comprises three domains, Cnl, Ch2 and Ch3. Each light chain comprises a light chain variable region (abbreviated herein as LCVR or Vl) and a light chain constant region. The light chain constant region comprises one domain (ClI). The Vh and Vl regions can be further subdivided into regions of hypervariability, termed complementarity determining regions
WO 2019/028367
PCT/US2018/045195 (CDRs), interspersed with regions that are more conserved, termed framework regions (FR). Each Vh and Vl is composed of three CDRs and four FRs, arranged from aminoterminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In different embodiments of the invention, the FRs of the anti-IL-4R antibody (or antigen-binding portion thereof) may be identical to the human germline sequences, or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs.
[0077] The term “antibody,” as used herein, also includes antigen-binding fragments of full antibody molecules. The terms “antigen-binding portion” of an antibody, “antigenbinding fragment” of an antibody, and the like, as used herein, include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds an antigen to form a complex. Antigen-binding fragments of an antibody may be derived, e.g., from full antibody molecules using any suitable standard techniques such as proteolytic digestion or recombinant genetic engineering techniques involving the manipulation and expression of DNA encoding antibody variable and optionally constant domains. Such DNA is known and/or is readily available from, e.g., commercial sources, DNA libraries (including, e.g, phage-antibody libraries), or can be synthesized. The DNA may be sequenced and manipulated chemically or by using molecular biology techniques, for example, to arrange one or more variable and/or constant domains into a suitable configuration, or to introduce codons, create cysteine residues, modify, add or delete amino acids, etc.
[0078] Non-limiting examples of antigen-binding fragments include: (i) Fab fragments;
(ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of the amino acid residues that mimic the hypervariable region of an antibody (e.g., an isolated complementarity determining region (CDR) such as a CDR3 peptide), or a constrained FR3-CDR3-FR4 peptide. Other engineered molecules, such as domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g. monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains, are also encompassed within the expression antigen-binding fragment, as used herein.
[0079] An antigen-binding fragment of an antibody will typically comprise at least one variable domain. The variable domain may be of any size or amino acid composition and
WO 2019/028367
PCT/US2018/045195 will generally comprise at least one CDR that is adjacent to or in frame with one or more framework sequences. In antigen-binding fragments having a Vh domain associated with a Vl domain, the Vh and Vl domains may be situated relative to one another in any suitable arrangement. For example, the variable region may be dimeric and contain VhVh, Vh-Vl or Vl-Vl dimers. Alternatively, the antigen-binding fragment of an antibody may contain a monomeric Vh or Vl domain.
[0080] In certain embodiments, an antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain. Nonlimiting, exemplary configurations of variable and constant domains that may be found within an antigen-binding fragment of an antibody of the present invention include: (i) VhChI; (ii) Vh-Ch2; (iii) Vh-Ch3; (iv) Vh-Ch1-Ch2; (v) Vh-Ch1-Ch2-Ch3; (vi) Vh-Ch2Ch3; (vii) Vh-Cl; (viii) Vl-Ch1; (ix) Vl-Ch2; (x) Vl-Ch3; (xi) Vl-Ch1-Ch2; (xii) Vl-Ch1Ch2-Ch3; (xiii) Vl-Ch2-Ch3; and (xiv) Vl-Cl. In any configuration of variable and constant domains, including any of the exemplary configurations listed above, the variable and constant domains may be either directly linked to one another or may be linked by a full or partial hinge or linker region. A hinge region may consist of at least 2 (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids which result in a flexible or semi-flexible linkage between adjacent variable and/or constant domains in a single polypeptide molecule. Moreover, an antigen-binding fragment of an antibody of the present invention may comprise a homo-dimer or hetero-dimer (or other multimer) of any of the variable and constant domain configurations listed above in non-covalent association with one another and/or with one or more monomeric Vh or Vl domain (e.g, by disulfide bond(s)).
[0081] The term antibody, as used herein, also includes multispecific (e.g, bispecific) antibodies. A multispecific antibody or antigen-binding fragment of an antibody will typically comprise at least two different variable domains, wherein each variable domain is capable of specifically binding to a separate antigen or to a different epitope on the same antigen. Any multispecific antibody format may be adapted for use in the context of an antibody or antigen-binding fragment of an antibody of the present invention using routine techniques available in the art. For example, the present invention includes methods comprising the use of bispecific antibodies wherein one arm of an immunoglobulin is specific for IL-4Ra or a fragment thereof, and the other arm of the immunoglobulin is specific for a second therapeutic target or is conjugated to a therapeutic moiety. Exemplary bispecific formats that can be used in the context of the present invention include, without limitation, e.g, scFv-based or diabody bispecific formats, IgG-scFv
WO 2019/028367
PCT/US2018/045195 fusions, dual variable domain (DVD)-Ig, Quadroma, knobs-into-holes, common light chain (e.g., common light chain with knobs-into-holes, etc.), CrossMab, CrossFab, (SEED) body, leucine zipper, Duobody, IgGl/IgG2, dual acting Fab (DAF)-IgG, and Mab2 bispecific formats (see, e.g., Klein et al. 2012, mAbs 4:6, 1-11, and references cited therein, for a review of the foregoing formats). Bispecific antibodies can also be constructed using peptide/nucleic acid conjugation, e.g, wherein unnatural amino acids with orthogonal chemical reactivity are used to generate site-specific antibody oligonucleotide conjugates which then self-assemble into multimeric complexes with defined composition, valency and geometry. (See, e.g., Kazane et al., J. Am. Chem. Soc. [Epub: Dec. 4, 2012]).
[0082] The antibodies used in the methods of the present invention may be human antibodies. The term “human antibody,” as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies of the invention may nonetheless include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs and in particular CDR3. However, the term “human antibody,” as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
[0083] The antibodies used in the methods of the present invention may be recombinant human antibodies. The term “recombinant human antibody,” as used herein, is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described further below), antibodies isolated from a recombinant, combinatorial human antibody library (described further below), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g, Taylor et al. (1992) Nucl. Acids Res. 20:6287-6295) or antibodies prepared, expressed, created or isolated by any other means that involves splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of
WO 2019/028367
PCT/US2018/045195 the Vh and Vl regions of the recombinant antibodies are sequences that, while derived from and related to human germline Vh and Vl sequences, may not naturally exist within the human antibody germline repertoire in vivo.
[0084] According to certain embodiments, the antibodies used in the methods of the present invention specifically bind IL-4Ra. The term “specifically binds,” or the like, means that an antibody or antigen-binding fragment thereof forms a complex with an antigen that is relatively stable under physiologic conditions. Methods for determining whether an antibody specifically binds to an antigen are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like. For example, an antibody that “specifically binds” IL-4Ra, as used in the context of the present invention, includes antibodies that bind IL-4Ra or portion thereof with a Kd of less than about 500 nM, less than about 300 nM, less than about 200 nM, less than about 100 nM, less than about 90 nM, less than about 80 nM, less than about 70 nM, less than about 60 nM, less than about 50 nM, less than about 40 nM, less than about 30 nM, less than about 20 nM, less than about 10 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM or less than about 0.5 nM, as measured in a surface plasmon resonance assay. An isolated antibody that specifically binds human IL-4Ra may, however, have cross-reactivity to other antigens, such as IL-4Ra molecules from other (non-human) species.
[0085] According to certain exemplary embodiments of the present invention, the IL4/IL-13 pathway inhibitor is an anti-IL-4Ra antibody, or antigen-binding fragment thereof comprising a heavy chain variable region (HCVR), light chain variable region (LCVR), and/or complementarity determining regions (CDRs) comprising any of the amino acid sequences of the anti-IL-4R antibodies as set forth in US Patent No. 7,608,693. In certain exemplary embodiments, the anti-IL-4Ra antibody or antigen-binding fragment thereof that can be used in the context of the methods of the present invention comprises the heavy chain complementarity determining regions (HCDRs) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 1 and the light chain complementarity determining regions (LCDRs) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 2. According to certain embodiments, the anti-IL-4Ra antibody or antigen-binding fragment thereof comprises three HCDRs (HCDR1, HCDR2 and HCDR3) and three LCDRs (LCDR1, LCDR2 and LCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO: 3; the HCDR2 comprises the amino acid sequence of SEQ ID NO: 4; the HCDR3 comprises the
WO 2019/028367
PCT/US2018/045195 amino acid sequence of SEQ ID NO: 5; the LCDR1 comprises the amino acid sequence of SEQ ID NO: 6; the LCDR2 comprises the amino acid sequence of SEQ ID NO: 7; and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 8. In yet other embodiments, the anti-IL-4R antibody or antigen-binding fragment thereof comprises an HCVR comprising SEQ ID NO: 1 and an LCVR comprising SEQ ID NO: 2. In certain embodiments, the methods of the present invention comprise the use of an anti-IL-4R antibody, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9. In some embodiments, the anti-IL-4R antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 10. An exemplary antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10 is the fully human anti-IL-4R antibody known as dupilumab. According to certain exemplary embodiments, the methods of the present invention comprise the use of dupilumab, or a bioequivalent thereof. The term “bioequivalent”, as used herein, refers to anti-IL-4R antibodies or IL-4R-binding proteins or fragments thereof that are pharmaceutical equivalents or pharmaceutical alternatives whose rate and/or extent of absorption do not show a significant difference with that of dupilumab when administered at the same molar dose under similar experimental conditions, either single dose or multiple dose. In the context of the invention, the term refers to antigen-binding proteins that bind to IL-4R which do not have clinically meaningful differences with dupilumab in their safety, purity and/or potency.
[0086] Other anti-IL-4Ra antibodies that can be used in the context of the methods of the present invention include, e.g., the antibody referred to and known in the art as AMG317 (Corren et al., 2010, Am JRespir Crit Care Med., 757(8):788-796), or MEDI 9314, or any of the anti-IL-4Ra antibodies as set forth in US Patent No. 7,186,809, US Patent No. 7,605,237, US Patent No. 7,638,606, US Patent No. 8,092,804, US Patent No. 8,679,487, or US Patent No. 8,877,189.
[0087] The anti-IL-4Ra antibodies used in the context of the methods of the present invention may have pH-dependent binding characteristics. For example, an anti-IL-4Ra antibody for use in the methods of the present invention may exhibit reduced binding to IL-4Ra at acidic pH as compared to neutral pH. Alternatively, an anti-IL-4Ra antibody of the invention may exhibit enhanced binding to its antigen at acidic pH as compared to neutral pH. The expression acidic pH includes pH values less than about 6.2, e.g., about 6.0, 5.95, 5.9, 5.85, 5.8, 5.75, 5.7, 5.65, 5.6, 5.55, 5.5, 5.45, 5.4, 5.35, 5.3, 5.25, 5.2, 5.15,
WO 2019/028367
PCT/US2018/045195
5.1, 5.05, 5.0, or less. As used herein, the expression neutral pH means a pH of about 7.0 to about 7.4. The expression neutral pH includes pH values of about 7.0, 7.05, 7.1, 7.15, 7.2, 7.25, 7.3, 7.35, and 7.4.
[0088] In certain instances, “reduced binding to IL-4Ra at acidic pH as compared to neutral pH” is expressed in terms of a ratio of the Kd value of the antibody binding to IL4Ra at acidic pH to the Kd value of the antibody binding to IL-4Ra at neutral pH (or vice versa). For example, an antibody or antigen-binding fragment thereof may be regarded as exhibiting reduced binding to IL-4Ra at acidic pH as compared to neutral pH for purposes of the present invention if the antibody or antigen-binding fragment thereof exhibits an acidic/neutral Kd ratio of about 3.0 or greater. In certain exemplary embodiments, the acidic/neutral Kd ratio for an antibody or antigen-binding fragment of the present invention can be about 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 20.0, 25.0, 30.0, 40.0, 50.0, 60.0, 70.0, 100.0, or greater.
[0089] Antibodies with pH-dependent binding characteristics may be obtained, e.g., by screening a population of antibodies for reduced (or enhanced) binding to a particular antigen at acidic pH as compared to neutral pH. Additionally, modifications of the antigen-binding domain at the amino acid level may yield antibodies with pH-dependent characteristics. For example, by substituting one or more amino acids of an antigenbinding domain (e.g., within a CDR) with a histidine residue, an antibody with reduced antigen-binding at acidic pH relative to neutral pH may be obtained. As used herein, the expression acidic pH means a pH of 6.0 or less.
Pharmaceutical Compositions [0090] The present invention includes methods that comprise administering an IL-4/IL13 pathway inhibitor to a subject wherein the IL-4/IL-13 pathway inhibitor is contained within a pharmaceutical composition. The pharmaceutical compositions of the invention may be formulated with suitable carriers, excipients, and other agents that provide suitable transfer, delivery, tolerance, and the like. A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LIPOFECTIN™), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing
WO 2019/028367
PCT/US2018/045195 carbowax. See also Powell et al. Compendium of excipients for parenteral formulations PDA (1998) J Pharm Sci Technol 52:238-311.
[0091] Various delivery systems are known and can be used to administer the pharmaceutical composition of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the mutant viruses, receptor mediated endocytosis (see, e.g., Wu et al., 1987, J. Biol. Chem. 262: 4429-4432). Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The composition may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g, oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents.
[0092] A pharmaceutical composition of the present invention can be delivered subcutaneously or intravenously with a standard needle and syringe. In addition, with respect to subcutaneous delivery, a pen delivery device readily has applications in delivering a pharmaceutical composition of the present invention. Such a pen delivery device can be reusable or disposable. A reusable pen delivery device generally utilizes a replaceable cartridge that contains a pharmaceutical composition. Once all of the pharmaceutical composition within the cartridge has been administered and the cartridge is empty, the empty cartridge can readily be discarded and replaced with a new cartridge that contains the pharmaceutical composition. The pen delivery device can then be reused. In a disposable pen delivery device, there is no replaceable cartridge. Rather, the disposable pen delivery device comes prefilled with the pharmaceutical composition held in a reservoir within the device. Once the reservoir is emptied of the pharmaceutical composition, the entire device is discarded.
[0093] In certain situations, the pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump may be used. In another embodiment, polymeric materials can be used; see, Medical Applications of Controlled Release, Langer and Wise (eds.), 1974, CRC Pres., Boca Raton, Florida. In yet another embodiment, a controlled release system can be placed in proximity of the composition’s target, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, 1984, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138). Other controlled release systems are discussed in the review by Langer, 1990, Science 249:1527-1533.
WO 2019/028367
PCT/US2018/045195 [0094] The injectable preparations may include dosage forms for intravenous, subcutaneous, intracutaneous and intramuscular injections, drip infusions, etc. These injectable preparations may be prepared by known methods. For example, the injectable preparations may be prepared, e.g., by dissolving, suspending or emulsifying the antibody or its salt described above in a sterile aqueous medium or an oily medium conventionally used for injections. As the aqueous medium for injections, there are, for example, physiological saline, an isotonic solution containing glucose and other auxiliary agents, etc., which may be used in combination with an appropriate solubilizing agent such as an alcohol (e.g, ethanol), a polyalcohol (e.g., propylene glycol, polyethylene glycol), a nonionic surfactant [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)], etc. As the oily medium, there are employed, e.g., sesame oil, soybean oil, etc., which may be used in combination with a solubilizing agent such as benzyl benzoate, benzyl alcohol, etc. The injection thus prepared is preferably filled in an appropriate ampoule.
[0095] Advantageously, the pharmaceutical compositions for oral or parenteral use described above are prepared into dosage forms in a unit dose suited to fit a dose of the active ingredients. Such dosage forms in a unit dose include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc.
[0096] Exemplary pharmaceutical compositions comprising an anti-IL-4R antibody that can be used in the context of the present invention are disclosed, e.g., in US Patent 8,945,559.
Administration Regimens [0097] The present invention includes methods comprising administering to a subject an IL-4/IL-13 pathway inhibitor at a dosing frequency of about four times a week, twice a week, once a week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every eight weeks, once every twelve weeks, or less frequently so long as a therapeutic response is achieved. In certain embodiments involving the administration of an IL-4/IL-13 pathway inhibitor (e.g., an anti-IL-4R antibody), once a week dosing at an amount of about 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, or 300 mg, is employed. In certain embodiments involving the administration of an anti-IL-4R antibody, once in 2 weeks dosing at an amount of about 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, or 300 mg, is employed.
[0098] According to certain embodiments of the present invention, multiple doses of an IL-4/IL-13 pathway inhibitor may be administered to a subject over a defined time course.
WO 2019/028367
PCT/US2018/045195
The methods according to this aspect of the invention comprise sequentially administering to a subject multiple doses of an IL-4/IL-13 pathway inhibitor. As used herein, sequentially administering means that each dose of IL-4/IL-13 pathway inhibitor is administered to the subject at a different point in time, e.g., on different days separated by a predetermined interval (e.g., hours, days, weeks or months). The present invention includes methods that comprise sequentially administering to the patient a single initial dose of an IL-4/IL-13 pathway inhibitor, followed by one or more secondary doses of the IL-4/IL-13 pathway inhibitor, and optionally followed by one or more tertiary doses of the IL-4/IL-13 pathway inhibitor.
[0099] The terms initial dose, secondary doses, and tertiary doses, refer to the temporal sequence of administration of the IL-4/IL-13 pathway inhibitor. Thus, the initial dose is the dose that is administered at the beginning of the treatment regimen (also referred to as the baseline dose); the secondary doses are the doses that are administered after the initial dose; and the tertiary doses are the doses that are administered after the secondary doses. The initial, secondary, and tertiary doses may all contain the same amount of IL-4/IL-13 pathway inhibitor, but generally may differ from one another in terms of frequency of administration. In certain embodiments, however, the amount of IL-4/IL-13 pathway inhibitor contained in the initial, secondary and/or tertiary doses varies from one another (e.g, adjusted up or down as appropriate) during the course of treatment. In certain embodiments, the initial dose comprises a first amount of the antibody or antigen-binding fragment thereof and the one or more secondary doses each comprise a second amount of the antibody or antigen-binding fragment thereof. In some embodiments, the first amount of antibody or fragment thereof (initial dose) is 1.5x, 2x, 2.5x, 3x, 3.5x, 4x, or 5x the second amount of the antibody or antigen-binding fragment thereof (secondary dose). In certain embodiments, one or more (e.g., 1,2,3, 4, or 5) doses are administered at the beginning of the treatment regimen as loading doses followed by subsequent doses that are administered on a less frequent basis (e.g., maintenance doses). For example, an IL-4/IL-13 pathway inhibitor may be administered to a patient in need thereof at a loading dose of about 300mg to about 600mg followed by one or more maintenance doses of about 25mg to about 400mg. In one embodiment, the initial dose and the one or more secondary doses each include lOmg to 600mg of the IL4/IL-13 pathway inhibitor, e.g., lOOmg to 400mg of the IL-4/IL-13 pathway inhibitor, e.g, lOmg, 25mg, 50mg, lOOmg, 150mg, 200mg, 250mg, 300mg, 400mg or 500mg of the IL4/IL-13 pathway inhibitor. In one embodiment, the initial dose is 2x the secondary dose.
WO 2019/028367
PCT/US2018/045195 [00100] In one exemplary embodiment of the present invention, each secondary and/or tertiary dose is administered 1 to 14 (e.g., 1, 17, 2, 27, 3, 37, 4, 47, 5, 57, 6, 67, 7, 77, 8, 87, 9, 97, 10, 107, 11, 117, 12, 127, 13, 137, 14, 147, or more) weeks after the immediately preceding dose. The phrase the immediately preceding dose, as used herein, means, in a sequence of multiple administrations, the dose of IL-4/IL-13 pathway inhibitor that is administered to a patient prior to the administration of the very next dose in the sequence with no intervening doses.
[00101] The methods according to this aspect of the invention may comprise administering to a patient any number of secondary and/or tertiary doses of an IL-4/IL-13 pathway inhibitor. For example, in certain embodiments, only a single secondary dose is administered to the patient. In other embodiments, two or more (e.g, 2, 3, 4, 5, 6, 7, 8, or more) secondary doses are administered to the patient. Likewise, in certain embodiments, only a single tertiary dose is administered to the patient. In other embodiments, two or more (e.g, 2, 3, 4, 5, 6, 7, 8, or more) tertiary doses are administered to the patient.
[00102] In embodiments involving multiple secondary doses, each secondary dose may be administered at the same frequency as the other secondary doses. For example, each secondary dose may be administered to the patient 1 to 6 weeks after the immediately preceding dose. Similarly, in embodiments involving multiple tertiary doses, each tertiary dose may be administered at the same frequency as the other tertiary doses. For example, each tertiary dose may be administered to the patient 2 to 4 weeks after the immediately preceding dose. Alternatively, the frequency at which the secondary and/or tertiary doses are administered to a patient can vary over the course of the regimen.
[00103] The methods of the present invention, according to certain embodiments, comprise administering to the subject a corticosteroid (CS) in combination with an IL4/IL-13 pathway inhibitor (e.g, an anti-IL-4R antibody). As used herein, the expression in combination with means that the CS is administered before, after, or concurrent with the IL-4/IL-13 pathway inhibitor. The term “in combination with” also includes sequential or concomitant administration of IL-4/IL-13 pathway inhibitor and CS.
[00104] For example, when administered before the IL-4/IL-13 pathway inhibitor, the CS may be administered more than 72 hours, about 72 hours, about 60 hours, about 48 hours, about 36 hours, about 24 hours, about 12 hours, about 10 hours, about 8 hours, about 6 hours, about 4 hours, about 2 hours, about 1 hour, about 30 minutes, about 15 minutes or about 10 minutes prior to the administration of the IL-4/IL-13 pathway inhibitor. When administered after the IL-4/IL-13 pathway inhibitor, the CS may be
WO 2019/028367
PCT/US2018/045195 administered about 10 minutes, about 15 minutes, about 30 minutes, about 1 hour, about 2 hours, about 4 hours, about 6 hours, about 8 hours, about 10 hours, about 12 hours, about 24 hours, about 36 hours, about 48 hours, about 60 hours, about 72 hours, or more than 72 hours after the administration of the IL-4/IL-13 pathway inhibitor. Administration concurrent with the IL-4/IL-13 pathway inhibitor means that the CS is administered to the subject in a separate dosage form within less than 5 minutes (before, after, or at the same time) of administration of the IL-4/IL-13 pathway inhibitor, or administered to the subject as a single combined dosage formulation comprising both the CS and the IL-4/IL13 pathway inhibitor.
Dosage [00105] The amount of IL-4/IL-13 pathway inhibitor (e.g., anti-IL-4Ra antibody) administered to a subject according to the methods of the present invention is, generally, a therapeutically effective amount. As used herein, the phrase therapeutically effective amount means an amount of IL-4/IL-13 pathway inhibitor that results in one or more of: (a) a reduction in the severity or duration of a symptom of eosinophilic esophagitis; (b) a reduction in the number of eosinophils in esophagus; (c) increase in esophagus distensibility; (d) reduction in episodes of dysphagia; (e) prevention or alleviation of an allergic reaction; and (f) a reduction in the use or need for conventional allergy therapy (e.g, reduced or eliminated use of antihistamines, decongestants, nasal or inhaled steroids, anti-IgE treatment, epinephrine, etc.).
[00106] In the case of an anti-IL-4Ra antibody, a therapeutically effective amount can be from about 0.05 mg to about 600 mg, e.g., about 0.05 mg, about 0.1 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, or about 600 mg, of the anti-IL-4R antibody. In certain embodiments, 300 mg of an anti-IL-4R antibody is administered.
WO 2019/028367
PCT/US2018/045195 [00107] The amount of IL-4/IL-13 pathway inhibitor contained within the individual doses may be expressed in terms of milligrams of antibody per kilogram of patient body weight (i.e., mg/kg). For example, the IL-4/IL-13 pathway inhibitor (e.g., anti-IL-4Ra antibody) may be administered to a patient at a dose of about 0.0001 to about 100 mg/kg of patient body weight.
Selected Embodiments [00108] In Embodiment 1, the present invention includes a method of reducing dysphagia comprising: (a) selecting a patient with at least one of the following characteristics: (i) the patient exhibits >1 episodes of dysphagia per week; (ii) the patient has been treated previously with high-dose proton pump inhibitors (PPIs); and (iii) the patient has had at least one prior esophageal dilation; and (b) administering a therapeutically effective amount of a pharmaceutical composition comprising an interleukin-4/interleukin-13 (IL4/IL-13) pathway inhibitor to the patient in need thereof.
[00109] In Embodiment 2, the present invention includes a method of increasing esophageal distensibility comprising: (a) selecting a patient with at least one of the following characteristics: (i) the patient exhibits >1 episodes of dysphagia per week; (ii) the patient has been treated previously with high-dose PPIs; and (iii) the patient has had at least one prior esophageal dilation; and (b) administering a therapeutically effective amount of a pharmaceutical composition comprising an IL-4/IL-13 pathway inhibitor to the patient in need thereof.
[00110] In Embodiment 3, the present invention includes the method of Embodiment 1 or 2, wherein the patient has moderate-to-severe EoE.
[00111] In Embodiment 4, the present invention includes a method of treating, preventing or ameliorating at least one symptom or indication of active eosinophilic esophagitis (EoE) comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an IL-4/IL-13 pathway inhibitor to a patient in need thereof. [00112] In Embodiment 5, the present invention includes the method of any one of Embodiments 1 to 4, wherein the patient has one or more characteristics selected from the group consisting of: (1) the patient has >15 eosinophils per high powered field (hpf) in the esophagus prior to or at the time of the treatment (“baseline”); (2) prior treatment with at least one of high dose PPIs, esophageal dilation, corticosteroids, allergen withdrawal and/or diet modification; (3) the patient exhibits >1 episodes of dysphagia per week; (4) the patient is unresponsive or resistant to prior treatment with high dose PPIs or esophageal dilation; (5) the patient has a Straumann Dysphagia Instrument (SDI) score >2;
WO 2019/028367
PCT/US2018/045195 (6) the patient has an Eosinophilic Esophagitis Severity and Activity Index (EEsAI) score >30, >40, or >50; (7) the patient suffers from EoE for at least 3 years; (8) the patient, prior to or at the time of administration of the IL-4/IL-13 pathway inhibitor, has or is diagnosed with a disease or disorder selected from the group consisting of food allergy, atopic dermatitis, asthma, allergic rhinitis and allergic conjunctivitis; and (9) the patient has an elevated level of a biomarker selected from the group consisting of eotaxin-3, periostin, serum IgE (total and allergen-specific), IL-13, IL-5, serum thymus and activation regulated chemokine (TARC), thymic stromal lymphopoietin (TSLP), serum eosinophilic cationic protein (ECP), and eosinophil-derived neurotoxin (EDN).
[00113] In Embodiment 6, the present invention includes the method of any one of Embodiments 1 to 5, wherein administration of the IL-4/IL-13 pathway inhibitor results in improvement of an EoE-related parameter selected from the group consisting of: (a) reduction of at least 40% from baseline in dysphagia frequency and severity, as measured by Straumann Dysphagia Instrument (SDI) score; (b) reduction of 3 points from baseline in the SDI score; (c) reduction of more than 85% from baseline in peak intraepithelial eosinophil count in proximal, mid and/or distal regions of the esophagus; (d) increase of at least 10% from baseline in esophageal distensibility, as measured by impedance planimetry; (e) decrease of more than 50% from baseline in severity and extent of disease, as measured by EoE Histology Scoring System (HSS) score; and (f) reduction of more than 30% from baseline in dysphagia, as measured by Eosinophilic Esophagitis Severity and Activity Index (EEsAI) score.
[00114] In Embodiment 7, the present invention includes the method of any one of Embodiments 1 to 6, wherein the IL-4/IL-13 pathway inhibitor is an antibody or antigenbinding fragment thereof that specifically binds IL-4 receptor (IL-4R).
[00115] In Embodiment 8, the present invention includes the method of any one of Embodiments 1 to 7, wherein the IL-4/IL-13 pathway inhibitor is administered at a dose of about 50 - 600 mg.
[00116] In Embodiment 9, the present invention includes the method of any one of Embodiments 1 to 8, wherein the IL-4/IL-13 pathway inhibitor is administered at a dose of about 300 mg.
[00117] In Embodiment 10, the present invention includes the method of any one of Embodiments 1 to 7, wherein the IL-4/IL-13 pathway inhibitor is administered at an initial dose followed by one or more secondary doses, wherein each secondary dose is administered 1 to 4 weeks after the immediately preceding dose.
WO 2019/028367
PCT/US2018/045195 [00118] In Embodiment 11, the present invention includes the method of Embodiment 10, wherein the initial dose comprises 50 - 600mg of the IL-4/IL-13 pathway inhibitor.
[00119] In Embodiment 12, the present invention includes the method of Embodiment 10 or 11, wherein each secondary dose comprises 25 - 400mg of the IL-4/IL-13 pathway inhibitor.
[00120] In Embodiment 13, the present invention includes the method of any one of Embodiments 10 to 12, wherein the initial dose comprises 600mg of the IL-4/IL-13 pathway inhibitor and each secondary dose comprises 300mg of the IL-4/IL-13 pathway inhibitor.
[00121] In Embodiment 14, the present invention includes the method of Embodiment 13, wherein each secondary dose is administered one week after the immediately preceding dose.
[00122] In Embodiment 15, the present invention includes the method of Embodiment 13, wherein each secondary dose is administered 2 weeks after the immediately preceding dose.
[00123] In Embodiment 16, the present invention includes the method of any one of Embodiments 4 to 15, wherein the symptom or indication of EoE is selected from the group consisting of eosinophilic infiltration of the esophagus, thickening of the esophageal wall, food refusal, vomiting, abdominal pain, heartbum, regurgitation, dysphagia and food impaction.
[00124] In Embodiment 17, the present invention includes the method of any one of Embodiments 1 to 16, wherein the patient exhibits an allergic reaction to a food allergen contained in a food item selected from the group consisting of a dairy product, egg, wheat, soy, com, fish, shellfish, peanut, a tree nut, beef, chicken, oat, barley, pork, green beans, apple and pineapple.
[00125] In Embodiment 18, the present invention includes the method of any one of Embodiments 1 to 17, wherein the patient exhibits an allergic reaction to anon-food allergen derived from one of dust, pollen, mold, plant, cat, dog or insect.
[00126] In Embodiment 19, the present invention includes the method of any one of Embodiments 1 to 18, wherein the administration of the IL-4/IL-13 pathway inhibitor results in reducing the level of an EoE-associated biomarker in the subject.
[00127] In Embodiment 20, the present invention includes the method of Embodiment 19, wherein the EoE-associated biomarker is selected from the group consisting of eotaxin-3,
WO 2019/028367
PCT/US2018/045195 periostin, serum IgE (total and allergen-specific), IL-13, IL-5, serum TARC, TSLP, serum ECP, and EDN.
[00128] In Embodiment 21, the present invention includes the method of any one of Embodiments 1 to 20, wherein the IL-4/IL-13 pathway inhibitor is administered in combination with a second therapeutic agent or therapy, wherein the second therapeutic agent or therapy is selected from the group consisting of an IL-1 beta inhibitor, an IL-5 inhibitor, an IL-9 inhibitor, an IL-13 inhibitor, an IL-17 inhibitor, an IL-25 inhibitor, a TNFalpha inhibitor, an eotaxin-3 inhibitor, an IgE inhibitor, a prostaglandin D2 inhibitor, an immunosuppressant, a topical corticosteroid, an oral corticosteroid, a systemic corticosteroid, an inhaled corticosteroid, a glucocorticoid, a proton pump inhibitor, a NSAID, esophagus dilation, allergen removal and diet management.
[00129] In Embodiment 22, the present invention includes the method of any one of Embodiments 1 to 21, wherein the IL-4/IL-13 pathway inhibitor is selected from the group consisting of an anti-IL-4 antibody, an anti-IL-13 antibody, an anti-IL-4/IL-13 bispecific antibody, an IL-4 receptor (IL-4R) inhibitor, and an anti-IL-4R antibody.
[00130] In Embodiment 23, the present invention includes the method of Embodiment 22, wherein the IL-4/IL-13 pathway inhibitor is an IL-4R inhibitor.
[00131] In Embodiment 24, the present invention includes the method of Embodiment 22, wherein the IL-4/IL-13 pathway inhibitor is an anti-IL-4 antibody.
[00132] In Embodiment 25, the present invention includes the method of Embodiment 22, wherein the IL-4/IL-13 pathway inhibitor is an anti-IL-13 antibody.
[00133] In Embodiment 26, the present invention includes the method of Embodiment 22, wherein the IL-4/IL-13 pathway inhibitor is a bispecific antibody that specifically binds to IL-4 and IL-13.
[00134] In Embodiment 27, the present invention includes the method of any one of Embodiments 1 to 23, wherein the IL-4/IL-13 pathway inhibitor is an antibody or antigenbinding fragment thereof that binds IL-4Ra and prevents the interaction of IL-4 and/or IL13 with a type 1 or type 2 IL-4 receptor.
[00135] In Embodiment 28, the present invention includes the method of Embodiment 27, wherein the antibody or antigen-binding fragment thereof prevents the interaction of IL-4 with both type 1 and type 2 IL-4 receptors.
[00136] In Embodiment 29, the present invention includes the method of Embodiment 28, wherein the antibody or antigen-binding fragment thereof comprises the heavy chain complementarity determining regions (HCDRs) of a heavy chain variable region (HCVR)
WO 2019/028367
PCT/US2018/045195 comprising the amino acid sequence of SEQ ID NO: 1 and the light chain complementarity determining regions (LCDRs) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 2.
[00137] In Embodiment 30, the present invention includes the method of Embodiment 28, wherein the antibody or antigen-binding fragment thereof comprises three HCDRs (HCDR1, HCDR2 and HCDR3) and three LCDRs (LCDR1, LCDR2 and LCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO: 3; the HCDR2 comprises the amino acid sequence of SEQ ID NO: 4; the HCDR3 comprises the amino acid sequence of SEQ ID NO: 5; the LCDR1 comprises the amino acid sequence of SEQ ID NO: 6; the LCDR2 comprises the amino acid sequence of SEQ ID NO: 7; and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 8.
[00138] In Embodiment 31, the present invention includes the method of Embodiment 30, wherein the HCVR comprises the amino acid sequence of SEQ ID NO: 1 and the LCVR comprises the amino acid sequence of SEQ ID NO: 2.
[00139] In Embodiment 32, the present invention includes the method of any one of Embodiments 29 to 31, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10.
[00140] In Embodiment 33, the present invention includes the method of any one of Embodiments 1 to 31, wherein the IL-4/IL-13 pathway inhibitor is dupilumab or a bioequivalent thereof.
[00141] In Embodiment 34, the present invention includes the method of Embodiment 23, wherein the IL-4R inhibitor is AMG317 or MEDI9314.
EXAMPLES [00142] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the methods and compositions of the invention, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.
WO 2019/028367
PCT/US2018/045195
Example 1: Clinical trial of subcutaneously administered dupilumab in adult patients with active, moderate-to-severe eosinophilic esophagitis (EoE) [00143] This study is a 32-week, double-blind, randomized, placebo-controlled study to investigate the efficacy, safety, tolerability and immunogenicity of dupilumab in adult patients with active EoE. Dupilumab is a fully human anti-IL-4R antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; an HCVR/LCVR amino acid sequence pair comprising SEQ ID NOs: 1 /2; and heavy and light chain CDR sequences comprising SEQ ID NOs: 3-8.
Study Objectives [00144] The primary objective of the study was to assess the clinical efficacy of repeat subcutaneous (SC) doses of dupilumab, compared with placebo, to relieve symptoms in adult patients with active, moderate to severe EoE.
[00145] The secondary objectives of the study were: (1) to assess the safety, tolerability, and immunogenicity of SC doses of dupilumab in adult patients with active, moderate to severe EoE; (2) to assess the effect of dupilumab on esophageal eosinophilic infiltration; and (3) to evaluate the pharmacokinetics (PK) of dupilumab in adult patients with EoE. [00146] The exploratory objective of the study was to assess the effect of dupilumab on other esophageal biopsy pathologic features associated with EoE.
Study Design [00147] This was a multicenter, double-blind, randomized, placebo-controlled study investigating the efficacy, safety, tolerability, PK, and immunogenicity of dupilumab in adult patients with EoE.
[00148] After providing informed consent, patient eligibility was assessed at the screening visit (to occur between day -35 and day -1). Patients who met eligibility criteria underwent day 1 baseline assessments. Patients were randomized in a 1:1 ratio to receive dupilumab or placebo during the 12-week double-blind treatment phase. After the 12week double-blind treatment phase, patients were followed off study drug for an additional 16 weeks.
[00149] Patients received concomitant medications (except for prohibited medications [see below]) as needed, while continuing study treatment. Efficacy, safety, and laboratory assessments, and samples for dupilumab concentration and potential anti-drug antibody (ADA) response to dupilumab, as well as research samples were performed or collected at specified time points throughout the study.
WO 2019/028367
PCT/US2018/045195
Study Population [00150] The target population included adult (18 to 65 years old) male or female patients with active EoE.
[00151] Inclusion Criteria: A patient had to meet the following criteria to be eligible for inclusion in the study:
(1) Male or female, 18 to 65 years old;
(2) Documented diagnosis of EoE by endoscopy prior to or at screening. Note: Must include a demonstration of intraepithelial eosinophilic infiltration (peak cell count >15 eosinophils/high power field [eos/hpf] [400X]) from esophageal biopsy specimens from endoscopy performed no more than 2 weeks after at least 8 weeks of treatment with high dose (or twice-daily dosing) proton pump inhibitors (PPIs);
(3) History (by patient report) of on average at least 2 episodes of dysphagia (with intake of solids off anti-inflammatory therapy) per week in the 4 weeks prior to screening and on average at least 2 episodes of documented dysphagia per week in the weeks between screening and baseline; dysphagia is defined as trouble swallowing solid food, or having solid food stick, by patient report;
(4) Must remain on a stabilized diet for at least 6 weeks prior to screening and during the course of the study; stable diet is defined as no initiation of single or multiple elimination diets or reintroduction of previously eliminated food groups;
(5) SDI PRO score >5 at screening and baseline;
(6) Documented history of or presence of 1 or more of any of the following: allergic disease (e.g., allergic asthma, allergic rhinitis, AD, or food allergies), peripheral eosinophil counts >0.25 GI/L, serum total Immunoglobulin E (IgE) >100 kU/L;
(7) Willing and able to comply with all clinic visits and study-related procedures; able to understand and complete study-related questionnaires; provide signed informed consent; and (8) Endoscopy with photographs performed at screening, with a demonstration of intraepithelial eosinophilic infiltration (peak cell count >15 eos/hpf) in at least 2 of the 3 biopsied esophageal regions (proximal, mid, or distal).
[00152] Exclusion Criteria: A patient who met any of the following criteria was ineligible to participate in this study: (1) Prior participation in a dupilumab (anti-IL-4R) clinical trial; (2) Other causes of esophageal eosinophilia or the following diseases: hypereosinophilic syndromes, Churg-Strauss vasculitis, and eosinophilic gastroenteritis; (3) History of achalasia, active Helicobacter pylori infection, Crohn’s disease, ulcerative colitis, celiac
WO 2019/028367
PCT/US2018/045195 disease, and prior esophageal surgery prior to screening; (4) Any esophageal stricture unable to be passed with a standard, diagnostic, adult (9 tolO mm) upper endoscope or any critical esophageal stricture that requires dilation at screening; (5) History of bleeding disorders or esophageal varices; (6) Use of chronic aspirin, nonsteroidal agents, or anticoagulants within 2 weeks prior to screening. Patients should not stop these agents solely to become eligible for entry into this study; (7) Treatment with an investigational drug within 2 months or within 5 half-lives (if known), whichever is longer, prior to screening; (8) Use of systemic corticosteroids within 3 months or swallowed topical corticosteroids within 6 weeks prior to screening; (9) Use of inhaled or nasal corticosteroids within 3 months prior to screening and during the study, except stable dose for at least 3 months prior to screening biopsy, which cannot be changed during the study; (10) Treatment with oral immunotherapy (OIT) within 6 months prior to screening; (11) Allergen immunotherapy (sublingual immunotherapy [SLIT] and/or subcutaneous immunotherapy [SCIT], unless on stable dose for at least 1 year prior to screening; (12) The following treatments within 3 months before the screening visit, or any condition that, in the opinion of the investigator, is likely to require such treatment(s) during the 3 months of study treatment: Systemic immunosuppressive/immunomodulating drugs (e.g., omalizumab, cyclosporine, mycophenolate-mofetil, interferon-gamma [IFN-γ], Janus kinase inhibitors, azathioprine, methotrexate, leukotriene inhibitors [except stable dose for at least 3 months prior to screening], etc.); (13) Diagnosed with active parasitic infection; suspected parasitic infection, unless clinical and (if necessary) laboratory assessments have ruled out active infection before randomization; (14) Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or antifungals within 1 month prior to screening; (15) Use of oral antibiotics/anti-infectives within 2 weeks prior to screening; (16) Known or suspected immunosuppression, including history of invasive opportunistic infections (e.g., tuberculosis, non-tuberculous mycobacterial infections, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency, or prolonged infections suggesting an immune-compromised status, as judged by the investigator; (17) Known history of human immunodeficiency vims (HIV) infection; (18) Positive or indeterminate hepatitis B surface antigen (HBsAg) or hepatitis C antibody at screening; (19) Elevated transaminases (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]) more than 3 times the upper limit of normal (>3 x upper limit of normal [ULN]) at screening; (20) History of malignancy within 5 years prior to screening, except completely treated in situ
WO 2019/028367
PCT/US2018/045195 carcinoma of the cervix and completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin; (21) History of patient-reported alcohol or drug abuse within 6 months prior to screening; (22) Any other medical or psychological condition including relevant laboratory abnormalities at screening that, in the opinion of the investigator, suggest anew and/or insufficiently understood disease, may present an unreasonable risk to the study patient as a result of his/her participation in this clinical trial, may make patient’s participation unreliable, or may interfere with study assessments. The specific justification for patients excluded under this criterion will be noted in study documents (chart notes, case report form [CRF], etc.); (23) Severe concomitant illness(es) that, in the investigator’s judgment, would adversely affect the patient’s participation in the study; (24) Planned or anticipated use of any prohibited medications and procedures (see below) during study treatment; (25) Treatment with a live (attenuated) vaccine within 3 months prior to screening; (26) Patient or his/her immediate family is a member of the investigational team; (27) Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study; (28) Women unwilling to use adequate birth control, if of reproductive potential* and sexually active.
Study Treatments [00153] Investigational drug: Dupilumab SC, a loading dose of 600 mg on day 1 followed by weekly doses of 300 mg from week 1 to week 11 [00154] Placebo: Placebo (same formulation as dupilumab without the active substance, anti-IL-4R monoclonal antibody) SC, a volume matching the dupilumab loading dose on day 1 followed by weekly doses matching the volume of dupilumab weekly dose from week 1 to week 11.
[00155] Patients received SC dupilumab 300 mg or matching placebo qw during the 12week double-blind treatment phase. Patients received 2 injections (300-mg initial dose, followed by a 300-mg loading dose) on day 1, followed by weekly injections.
Permitted (concomitant) medications [00156] Treatment with concomitant medications was permitted during the study. This included treatment with contraceptives, stable dose of proton pump inhibitors (PPIs) (patients who were using PPIs at screening did not discontinue or change the dosing regimen prior to end of treatment [EOT] visit); stable dose (for at least 3 months prior to screening) of systemic leukotriene inhibitors, topical, nasal, and/or inhaled corticosteroids; oral antihistamines for any duration; and oral antibiotics for up to 2 weeks.
WO 2019/028367
PCT/US2018/045195
Restricted medications and procedures [00157] Restricted medications during duration of study included: (1) Medications used for the treatment of EoE (these were considered rescue medications): Swallowed topical corticosteroids, Systemic corticosteroids, Start or dose change of systemic leukotriene inhibitors, topical, nasal, and/or inhaled corticosteroids, and Systemic treatment for EoE with an immunosuppressive/immunomodulating substance (including, but not limited to, omalizumab, cyclosporine, mycophenolate-mofetil, azathioprine, methotrexate, IFN-γ, or other biologies); (2) Allergen immunotherapy (SCIT and SLIT were allowed if dose was stable for 1 year or more; however, OIT was prohibited); (3) Patients who were not using PPI in the 8 weeks prior to screening were prohibited from starting PPI therapy prior to EOT visit; (4) Treatment with a live (attenuated) vaccine (Chickenpox (varicella), FluMist-Influenza, Intranasal influenza, Measles (rubeola), Measles-mumps-rubella combination, Measles-mumps-rubella-varicella combination, Mumps, Oral polio (Sabin), Oral typhoid, Rubella, Smallpox (vaccinia), Yellow fever, Bacille Calmette-Guerin, Varicella zoster (shingles), Rotavirus); and (5) Treatment with an investigational drug (other than dupilumab) [00158] The following concomitant procedures were prohibited during study treatment (through week 12): (1) Major elective surgical procedures; (2) Esophageal dilation (considered rescue procedure); and (3) Diet change (patients were to remain on stable diet for at least 6 weeks prior to screening and during the course of the study; stable diet was defined as no initiation of single or multiple elimination diets or reintroduction of previously eliminated food groups).
Study Endpoints [00159] The primary efficacy endpoint was: Change in the Straumann Dysphagia Instrument (SDI) patient-reported outcome (PRO) score from baseline to week 10. [00160] The secondary endpoints were: Percent change in weekly Eosinophilic Esophagitis Activity Index (EEsAI) PRO score from baseline to week 10; Change in weekly EEsAI PRO score from baseline to week 10; Percent change in weekly EEsAI PRO score from baseline to week 12; Change in weekly EEsAI PRO score from baseline to week 12; Percent change in the SDI PRO score from baseline to week 10; Percent change in the SDI PRO score from baseline to week 12; Change in the SDI PRO score from baseline to week 12; Change in Adult Eosinophilic Esophagitis Quality of Life (EoEQOL-A) (questionnaire) PRO score from baseline to week 12; Percentage of patients with SDI PRO response at week 10; where response is defined as a decrease of at least 3 points
WO 2019/028367
PCT/US2018/045195 on the SDI compared to baseline; Percentage of patients who achieve >40% improvement in EEsAI score from baseline to week 10; Percent change in overall peak esophageal intraepithelial eos/hpf (400X) from baseline to week 12; Change in Eosinophilic Esophagitis-Endoscopic Reference Score (EoE-EREFs) (endoscopy visual anatomical score) from baseline to week 12; Percentage of patients with use of rescue medication or procedure (e.g., esophageal dilation) through week 12; and Incidence of treatmentemergent adverse events (TEAEs) [00161] The exploratory efficacy endpoints were: Change in mean esophageal intraepithelial eosinophil counts (eos/hpf) [calculated using peak count from each esophageal site] from baseline to week 12; Proportion of patients who achieve esophageal intraepithelial eosinophil count <1 eos/hpf at week 12; Change in Collins Histology Score from baseline to week 12; and Change in esophageal distensibility plateau as measured by functional lumen imaging from baseline to week 12.
Procedures and Assessments [00162] Screening/Baseline procedures: The following procedures were performed only at the screening and/or baseline visit for the sole purpose of determining study eligibility or characterizing the baseline population: serum FSH (for confirmation of menopausal status), serum total IgE, HBsAg, and hepatitis C antibody.
[00163] Efficacy procedures: Efficacy was assessed during the study at specified clinic visits using patient-reported outcomes (PROs), including Straumann Dysphagia Instrument (SDI), Eosinophilic Esophagitis Activity Index (EEsAI), and the Eosinophilic Esophagitis Quality of Life (EoE-QOL-A) questionnaire, as well as esophageal biopsies and photographs (endoscopy procedure). Measurement of inflammatory and remodeling esophageal features based on the Eosinophilic Esophagitis Edema rings Exudates Furrows and Strictures (EoE-EREFS) score was included as part of the endoscopy procedure. The endolumenal functional lumen imaging probe (EndoFLIP) procedure to measure esophageal distensibility was performed during the endoscopy procedures. The EoE Histological Scoring System (HSS) was used to measure 8 histologic features of EoE.
Straumann Dysphagia Instrument - Patient-reported Outcome [00164] The SDI is a non-validated PRO that has been used in clinical studies to determine the frequency and intensity of dysphagia (Straumann 2010). The SDI has a 1week recall period. Frequency of dysphagia events is graded on a 5-point scale: 0 = none, 1 = once per week, 2 = several times per week, 3 = once per day, and 4 = several times per day, and intensity of dysphagia events is graded on a 6-point scale: 0 = swallowing
WO 2019/028367
PCT/US2018/045195 unrestricted, 1 = slight sensation of resistance, 2 = slight retching with delayed passage, 3 = short period of obstruction necessitating intervention (e.g., drinking, breathing), 4 = longer-lasting period obstruction only removable by vomiting, and 5 = long-lasting complete obstruction requiring endoscopic intervention. The total SDI score ranges from 0 to 9. In the Straumann study, a clinical response (improvement) was defined as a decrease in SDI score of at least 3 points from baseline.
[00165] This assessment was completed by the patient electronically weekly in a questionnaire from the beginning of screening through end of study or early termination. Items utilized to quantitate the SDI were included in the EEsAI/SDI.
Eosinophilic Esophagitis Activity Index - Patient-reported Outcome [00166] The EEsAI is anon-validated, multimodular index in development at University Hospital Inselspital (Berne, Switzerland) (Schoepfer 2014), a part of the international EEsAI study group. The EEsAI PRO module (questionnaire) used in this study includes items related to the intensity and frequency of dysphagia, the influence of specific food groups on dysphagia symptoms, and other symptoms independent of eating or drinking (i.e., heartbum, acid regurgitation, and chest pain). The total EEsAI PRO score ranges from 0 to 100 (Figure 1), wherein higher scores indicate worse symptoms. The score consists of 5 parts: frequency of trouble swallowing, duration of trouble swallowing, pain when swallowing, visual dysphagia question, and avoidance, modification and slow eating (AMS). The EEsAI PRO utilizes 24-hour and 1-week recall periods.
[00167] This assessment was completed by the patient electronically daily and weekly in a questionnaire from the beginning of screening through end of study or early termination. Adult Eosinophilic Esophagitis Quality of Life Questionnaire - Patient-reported Outcome [00168] The EoE-QOL-A questionnaire is a validated disease-specific measure of healthrelated quality of life in EoE patients (Taft 2011). The instrument used in this study, the EoE-QOL-A v.3.0, includes 30 items related to established domains such as social functioning, emotional functioning, and disease impact of daily life experiences. The EoE-QOL-A has a 1-week recall period. The items are graded on a 5-point scale: ‘Not at All,’ ‘Slightly,’ ‘Moderately,’ ‘Quite a bit,’ and‘Extremely’.
[00169] This assessment was recorded by the patient in a questionnaire at baseline and then monthly through end of study or early termination.
WO 2019/028367
PCT/US2018/045195
Endoscopy with Esophageal Biopsies and Photographs [00170] Esophageal biopsies were obtained by endoscopy at the screening and week 12 visits. The screening endoscopy was performed during the screening period to allow results to be available prior to day -1 for assessment of eligibility. A total of 9 mucosal pinch biopsies were collected at each time point from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. Two samples from each region were used for the histology (needed for study inclusion criteria, as well as secondary endpoint). To participate in the study, patients had to have a peak intraepithelial eosinophil count >15 eos/hpf (400X) in at least 2 of the 3 esophageal regions sampled. Change in peak esophageal eos/hpf (400X) from baseline to week 12 was a secondary endpoint; this was determined by counting eosinophils in the most inflamed areas of each esophageal region sampled at each time point and calculating the change in the peak count at each site obtained at baseline compared to the count obtained at week 12. As an exploratory objective, the change in the mean of all 3 peak counts, i.e., the peak count at each of the 3 esophageal regions for each patient at each time point (screening and week 12) was calculated. Tissue blocks remaining after the histological assessment were banked for exploratory research.
[00171] The EoE-EREFS (edema, rings, exudates, furrows, strictures) was used to measure the endoscopically identified EoE esophageal mucosal inflammatory and remodeling features. This instrument includes a total of 17 items related to the presence and severity of esophageal features. The specific esophageal features include: rings (concentric rings around esophagus - absent, mild, moderate, severe, not applicable); strictures (narrowing of the esophagus - yes, no, not applicable); diameter of the stricture (if applicable); exudates (refer to white plaques - absent, mild, severe), furrows (vertical lines down the esophagus - absent, present); edema (loss of vascular markings of the mucosa - absent, present); crepe paper esophagus (absent, present); overall general appearance incorporating all endoscopically identified EoE findings (/. e., fixed rings, strictures, whitish exudates, furrowing, edema, and crepe paper mucosa). In addition, mucosal changes associated with gastroesophageal reflux disease were also recorded using the Los Angeles classification system for erosions (No Erosions or LA Classification A, B, C, D). The EoE esophageal characteristics were analyzed based on the EoE-EREFS, a validated scoring system for inflammatory and remodeling features of disease using both overall scores and scores for each individual characteristic (Hirano 2014). The modified EREFS score in this study was based on a total score range of 0 - 8; wherein higher scores
WO 2019/028367
PCT/US2018/045195 indicate greater impairment. Each score comprised: Edema: 0-1; Rings: 0-3; Exudates: 0-2; Furrows: 0 - 1; and Strictures: 0 - 1 to give a total possible score of 8.
[00172] The assessment of esophageal distensibility utilizing the endolumenal functional lumen imaging probe (EndoFLIP, Crospon, Ireland) was also performed to measure the diameter of the esophageal lumen and pressure (e.g., esophageal rigidity), with measurements taken as part of the endoscopy procedure performed at screening and week 12. The EndoFLIP device is a catheter based procedure that measures the cross sectional area at multiple sites along the esophagus with simultaneous intraluminal pressure recordings during volumetric distension of the esophagus. The analyses of cross sectional area versus pressure relationships of the esophagus allow for determination of esophageal compliance as well as the distensibility plateau (DP). The DP has been shown to be significantly reduced in patients with EoE compared to healthy controls (Kwiatek 2011). Moreover, the esophageal distensibility has been associated with outcomes of both food impaction and need for esophageal dilation (Nicodeme 2013).
[00173] The EoE-HSS generated separate severity (grade) and extent (stage) disease scores. The score was used to measure 8 histologic features (parameters) of EoE from 3 different regions (proximal, mid and distal) of the esophagus (Collins, et al. 2017). The 8 parameters include: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic cells, and lamina propria fibrosis. A scale of 0 - 3 was used for each parameter, both grade and stage (0 being least inflamed, normal). Total score range for each region for this study was 0-21 (excluding lamina propria parameter). The lamina propria assessment was excluded given that 50% of pinch biopsies would not be deep enough for lamina propria assessment. Total score per patient was calculated as (0 - 21 score x 3 regions = total possible score of 63 per time point). Two scores were generated per patient per time point, one each for grade (severity) and stage (extent).
[00174] Photographs were taken by the site as part of the endoscopic procedure and biopsy collection.
[00175] Safety Procedures: An AE is any untoward medical occurrence in a patient administered a study drug, which may or may not have a causal relationship with the study drug. Therefore, an AE is any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease that is temporally associated with the use of a study drug, whether or not considered related to the study drug. An AE also includes any
WO 2019/028367
PCT/US2018/045195 worsening (i.e., any clinically significant change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the study drug.
[00176] A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect and/or is an important medical event (e.g., such as an event may jeopardize the patient or may require intervention to prevent 1 of the other serious outcomes listed above.
[00177] Safety and tolerability was assessed by physical examinations, vital signs, electrocardiograms (ECGs), clinical laboratory tests, and clinical evaluations. Patients were asked to monitor all AEs experienced from the time of informed consent until their last study visit.
[00178] Pharmacokinetic and Antibody Procedures: Serum samples were collected for assay of dupilumab level and PK parameters were calculated using the dupilumab concentration data. Serum samples were collected for assay of ADA, and exploratory analyses.
Results [00179] Baseline Characteristics: Patients were randomized in a 1:1 ratio to receive a subcutaneous (SC) 600 mg dupilumab or SC placebo loading dose followed by weekly SC 300 mg dupilumab or SC placebo during the 12-week double-blind treatment phase. The randomization was stratified by baseline Straumann Dysphagia Instrument (SDI) PRO score (>5 and <7 versus >7). Baseline demographic and disease characteristics were generally balanced between the two groups (Tables 1 - 2), except for mean total IgE (dupilumab 217.8 kU/L; placebo 468.2 kU/L).
Table 1: Summary of Baseline Demographic Characteristics
Placebo(N=24) | 300 mg dupilumab qw (N=23) | |
Age, mean (SD), years | 36.1 (12.75) | 33.1 (8.70( |
Age Group, n (%) | ||
>18 to <40 years | 15 (62.5%) | 16 (69.6%) |
>40 to <65 years | 9 (37.5%) | 7 (30.4%) |
>65 years | 0 | 0 |
Male sex, n (%) | 10 (41.7%) | 13 (56.5%) |
Race: White, n (%) | 21 (87.5%) | 23 (100%) |
BMI (mean kg/m2) | 30.0 | ΤΊ.Ί |
WO 2019/028367
PCT/US2018/045195
Table 2: Summary of Baseline Disease Characteristics
Placebo(N=2 4) | 300 mg dupilumab qw (N=23) | |
Age at EoE onset, n (%) | ||
0 to 18 years | 4 (16.7%) | 7 (13.0%) |
19 to 24 years | 5 (20.8%) | 10(21.7%) |
25 to 50 years | 13 (54.2%) | 28 (65.2%) |
>50 years | 2 (8.3%) | 0 |
Duration of EoE years | 5.0 | 3.6 |
Blood Eosinophils (SD) GI/L | 0.43 (0.3) | 0.31 (0.2) |
Mean total IgE (SD) kU/L | 486.2 (900.7) | 217.8 (288.8) |
Mean SDI score (SD), (0 - 9) | 6.4(1.0) | 6.4(1.0) |
Weekly EEsAI score (0 - 100) | 62.2 | 62.0 |
Mean overall peak eosinophils/hpf (SD) | 101.1 (57.1) | 102.1 (53.5) |
EoE Histology Scoring System (0 - 63) | 27.4 | 27.9 |
# of dysphagia/week between screening and baseline | 12.4 | 13.7 |
EREF endoscopy score (0 - 9) | 4.3 | 3.9 |
Prior treatment with high dose PPIs, n (%) | 24 (100%) | 23 (100%) |
Prior topical corticosteroid use, n (%) | 20 (83.3) | 18 (78.3) |
Prior dilation, n (%) | 10(41.7) | 11 (47.8) |
Number of prior esophageal dilations (SD) | 3.9(3.3) | 5.7 (8.0) |
Any comorbid disease, n (%) | 19 (79.2) | 20 (87.0) |
WO 2019/028367
PCT/US2018/045195 [00180] Both groups showed a high level of atopic disease (Table 3).
Table 3: Summary of EoE/Allergic Disease Personal History
Placebo(N=2 4) | 300 mg dupilumab qw (N=23) | |
Patients with at least one Personal History | 24 (100%) | 23 (100%) |
Food allergy | 17 (70.8%) | 14 (60.9%) |
Allergic rhinitis | 15 (62.5%) | 16(69.6%) |
Other allergies (medications, animals, plants, mold, dust mites, etc.) | 12 (50.0%) | 14 (60.9%) |
Asthma | 9 (37.5%) | 11 (47.8%) |
Chronic sinusitis | 8 (33.3%) | 2 (8.7%) |
Hives | 6 (25.0%) | 7 (30.4%) |
Atopic Dermatitis | 5 (20.8%) | 3 (13.0%) |
Allergic conjunctivitis | 3 (12.5%) | 3 (13.0%) |
[00181] Efficacy Results: Table 4 summarizes the primary and secondary endpoint results. Dupilumab significantly improved subjective measures of EoE as reflected by dysphagia, as well as objective histologic and endoscopic measures of disease in EoE, compared with placebo. No patients received rescue medication/procedure during the 12week double-blind treatment period.
Table 4: Results - Primary and Secondary Endpoints*
Endpoint | Placebo1 (N=24) | 300 mg dupilumab qw1 (N=23) | LS mean difference vs placebo (95% CI) | P- value** |
Primary Efficacy Endpoint | ||||
Change of the SDI score from | N=14 | N=17 | ||
baseline to week 10 (range 0-9) | -1.3 (0.6) | -3.0 (0.5) | -1.7(-3.22,-0.16) | 0.0304 |
WO 2019/028367
PCT/US2018/045195
Secondary Efficacy Endpoint | ||||
% Change of weekly EEsAI score from baseline to week 10 (range 0 100) | N=13 | n-17 | ||
-11.3 (9.9) | -34.6 (9.1) | -23.2 (-49.68, 3.21) | 0.0850 | |
Change of weekly EEsAI score from baseline to week 10 (range 0-100) | N=13 | N=17 | ||
-9.0 (5.6) | -22.9 (5.0) | -13.9(-28.54, 0.78) | 0.0635 | |
% Change of weekly EEsAI score from baseline to week 12 (range 0 100) | N=8 | N=15 | ||
-3.3 (12.7) | -37.0(11.2) | -33.6 (-68.83, 1.54) | 0.0608 | |
Change of weekly EEsAI score from baseline to week 12 (range 0-100) | N=8 | N=15 | ||
-5.0 (7.1) | -26.1 (5.9) | -21.1 (-40.42,- 1.86) | 0.0318 | |
% Change of the SDI score from baseline to week 10 (range 0-9) | N=14 | N=17 | ||
-18.6 (9.0) | -45.0 98.4) | -26.5 (-50.52, - 2.39) | 0.0312 | |
Change of the SDI score from baseline to week 12 (range 0-9) | N=9 | N=16 | ||
-2.2 (0.7) | -2.9 (0.6) | -0.8 (-2.48, 0.96) | 0.3830 | |
% Change of the SDI score from baseline to week 12 (range 0-9) | N=9 | N=16 | ||
-31.8(10.7) | -42.8 (8.6) | -11.0(-37.46, 15.47) | 0.4147 | |
Change of EoE-QOL-A PRO total score from baseline to week 12 (range 1-5) | N=21 | N=23 | ||
0.47 (0.14) | 0.80 (0.14) | 0.33 (-0.05, 0.72) | 0.0910 | |
Proportion of patients with decrease of at least 3 points on the SDI from baseline to week 10 | N=14 | N=17 | ||
3 (12.5%) | 9(39.1%) | 26.6 (-3.04, 51.05) | 0.049 | |
Proportion of patients that achieve >40% improvement in EEsAI PRO score from baseline to week 10 | N=13 | N=17 | ||
2 (8.3%) | 6(26.1%) | 17.8(-11.54, 43.55) | 0.1365 | |
% Change of overall peak esophageal intraepithelial eosinophils/high power field (eos/hpf) (400X) from baseline to week 12 | N=22 | N=22 | ||
15.1 (12.5) | -91.8(12.3) | -107 (-141.4, - 72.46) | <0.0001 |
WO 2019/028367
PCT/US2018/045195
Change of EoE-EREFS total score (endoscopy visual anatomical score) from baseline to week 12 (range 0 9) | N=22 | N=22 | ||
-0.3 (0.33) | -1.9 (0.32) | -1.6 (-2,50, -0.68) | 0.0006 |
1 n represents # of patients with both baseline and post-baseline actual observed values * For continuous variables, multiple imputation/ANCOVA was used, LS (SE) was presented; for binary variables, patients with missing data were treated as non-responders and Fisher exact test was used for comparison, number and % of responder was presented. ** For the secondary endpoints, all p-values were nominal [00182] Dupilumab improved Straumann Dysphagia Instrument (SDI) score compared to placebo (-3 vs. -1.3, P=0.0304; 45.05% vs. 18.59%, P=0.0312) at week 10 (Table 4, Figure 2). 39% of dupilumab-treated patients achieved >3 reduction in SDI compared to 12.5% in the placebo group at week 10. At both week 10 and week 12, dupilumab improved both frequency and severity components of dysphagia of the SDI score (Figure 3)· [00183] Dupilumab numerically reduced EEsAI score (-34.6% vs. -11.3%, P=0.085) vs placebo through week 10 (Table 4, Figure 4).
[00184] Dupilumab significantly reduced peak eosinophil count (eos/hpf) from baseline to week 12, compared to placebo [-94.1 (-91.8%) vs -7.4 (+15.1%), 70.0001] (Tables 4 and 6). A reduction in eosinophil tissue infiltration was observed in all patients in the dupilumab group (Table 5). The dupilumab effect was similar on the proximal, mid and distal regions of the esophagus.
Table 5: Responder Analysis
Peak Eos (eos/hpf) at week 12 | Proportion of patients with response at week 12, n (%) | ||
300mg dupilumab | Placebo | P value | |
<1 | 3(13) | 0(0) | 0.1092 |
<6 | 14 (60.9) | 0(0) | <0.0001 |
<15 | 18 (78.3) | 0(0) | <0.0001 |
[00185] Dupilumab significantly reduced EREFS relative to placebo at week 12 (LS mean change p=0.0006, LS mean % change p=0.0004) (Table 4). Dupilumab significantly
WO 2019/028367
PCT/US2018/045195 reduced the total EREFS score, as well as the exudates and furrows subcomponents with trends observed for the edema, rings and strictures subcomponents (Figure 5).
[00186] Dupilumab significantly reduced both the total grade and stage scores of the EoEHSS from baseline to week 12, compared to placebo (P<0.001 vs placebo) (Table 6;
Figures 6 and 7). Dupilumab significantly reduced both grade (severity) and stage (extent) scores for basal zone hyperplasia (BZH), eosinophil inflammation (El), eosinophil surface layering (SL) and eosinophil abscess (EA) in proximal, mid and distal regions (Figures 8 and 9). Also, dupilumab reduced grade and stage scores for dilated intracellular spaces and surface alteration in all regions and distal apoptotic epithelial cells (Figures 10 and 11). [00187] Dupilumab significantly improved esophageal distensibility at week 12 compared to placebo (Table 6). An increase (improvement) in distensibility plateau was observed in more patients treated with dupilumab than placebo (Figure 12).
[00188] Table 6 summarizes the effect of dupilumab on subjective patient-reported outcomes on dysphagia and on clinician-assessed objective measures.
Table 6: Efficacy of dupilumab on subjective and objective EoE measures
PBO (N = 24) | Dupilumab 300 mg qw (N = 23) | LS mean difference vs PBO (95% CI) | |
SDI score | |||
BL score, mean (± SD) | 6.4 | 6.4 (1.04) | |
(1.01) | |||
Week l() | n = 14 | n = 17 | |
LS mean change from BL (± | -1.3 | -3.0 (0.5) | -1.7 (-3.2. -0.2)* |
SE) | (0.6) | ||
EEsAI score | |||
BL score, mean (± SD) | 62.2 | 62.0 (18.36) | |
(16.45) | |||
Week 10 | n = 13 | n= 17 | |
LS mean % change from BL (± | -11.3 | -34.6(9.1) | -23.2 (-49.7, 3.2)# |
SE) | (9.9) | ||
Peak esophageal | |||
intraepithelial (eos/hpf) | |||
BL score, mean (± SD) | 101.1 | 102.1 (53.5) |
WO 2019/028367
PCT/US2018/045195
(57.1) | |||
Week 12 | n = 22 | n = 22 | |
LS mean change from BL (± | -7.4 | -94.1 (9.52) | |
SE ) | (9.61) | ||
LS mean % change from BL (± | 15.1 ( | -91.8 ( 12.3) | -106.9(-141.4. |
SE) | 12.5) | -72.5)*** | |
Pts with response <6 eos/hpf. n | 0.0 | 14 (60.9) | |
(%) | |||
Pts with response <15 eos/hpf. | 0.0 | 18 (78.3) | |
n (%) | |||
EoE-EREFS score | |||
BL score, mean (± SD) | 4.3 | 3.9 (1.87) | |
(1.46) | |||
Week 12 | n = 22 | n = 23 | |
LS mean change from BL (± | -0.3 | -1. 9(0.3) | -1.6(-2.5, -0.7)*** |
SE) | (0.3) | ||
EoE-HSS | |||
BL score, mean (± SD) | 27.4 | 27.9 (6.05) | |
(6.46) | |||
Total - grade (severity) score | |||
Week 12 | n = 20 | n = 21 | |
All LS mean % change from | 3.9 (6.6) | -64.2 (6.4) | -68.1 (-85.8. |
BL(±SE) | -50.3)*** | ||
Distal LS mean % change from | 2.7 (5.3) | -57.0 (5.3) | -59.7 (-74.3. |
BL(±SE) | -45.1)*** | ||
Mid LS mean % change from | -8.1 | -70.8 (6.8) | -62.7 (-81.7. |
BL(±SE) | (7.0) | -43.7)*** | |
Proximal LS mean % change | 66.1 | -50.2 (24.5) | -1 16.3 (-188.0. |
from BL (± SE) | (27.4) | -44.5)*** | |
Total - stage (extent) score | |||
Week 12 | n = 20 | n = 21 | |
All LS mean % change from | -3.5 | -58.1 (4.7) | -54.6(-68.1, |
BL (± SE) | (5.0) | —41 0)*** |
WO 2019/028367
PCT/US2018/045195
Distal LS mean % change from | 5.1 (6.3) | -50.6 (6.3) | -55.6 (-73.2, |
BL (± SE) | -38.1)*** | ||
Mid LS mean % change from | -18.4 | -62.0 (5.5) | -43.5 (-59.1, |
BL (± SE) | (5.7) | -28.0)*** | |
Proximal LS mean % change | 43.1 | -46.9 (19.2) | -90.0 (-146.5, |
from BL (± SE) | (21.6) | -33.5)*** | |
Distensibility plateau (nun) | |||
BL. mean (± SD) | 17.60 | 18.66 (3.799) | |
(2.879) | |||
Week 12 | n = 12 | n= 12 | |
LS mean % change from BL (± | -6.2 | 1 1.8 (2.7) | 18.0(10.9. 25.2)*** |
SE) | (2.7) |
* P < 0.05, *** P < 0.001, # = P=0.085 vs PBO. SDI is a 9-item measure of dysphagia; score range 0-9 with higher scores indicating worse symptoms. EEsAI is a 5-item measure of dysphagia; score range 0-100 with higher scores indicating worse symptoms. The EoE Histology scoring system (EoEHSS) measures eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, surface epithelial alteration, dyskeratotic epithelial cells and dilated intercellular spaces. Lamina propria was excluded from the analysis, as -50% of pinch biopsies were not deep enough for assessment. Esophageal distensibility plateau is measured using the Functional Lumen Imaging Probe (EndoFLIP,® Crospon), a probe using impedance planimetry. The continuous efficacy endpoints were analyzed in the full analysis set (FAS) using multiple imputation (MI), followed by an analysis of covariance (ANCOVA) model with treatment group as fixed effect, and baseline SDI and the relevant baseline value as covariates. LS, least-squares; qw, every week [00189] Safety Results: Dupilumab was well tolerated in EoE patients. The most common treatment-emergent adverse events (TEAEs) were injection-site erythema (dupilumab 34.8%, placebo 8.3%) and nasopharyngitis (dupilumab 17.4%, placebo 4.2%).
Conclusion [00190] Compared to placebo, dupilumab demonstrated a statistically significant reduction in the primary endpoint, change from baseline in Straumann Dysphagia Instrument (SDI) at week 10, the LS mean difference in change from baseline at week 10 between dupilumab and placebo groups was -1.7 (p=0.0304). Improvements in other
WO 2019/028367
PCT/US2018/045195 subjective dysphagia measures including EEsAI (at week 10) and EOE-QOL (at week 12) were also noted. Finally, there were marked, statistical improvements in both histologic and visual endoscopic objective assessments of disease activity, including the percent change from baseline in peak eosinophils and absolute change from baseline in Eosinophilic Esophagitis Edema, Rings, Exudates, Furrows and Stricture (EoE-EREFS) score at week 12. Dupilumab treatment was generally safe and well tolerated. The most common TEAEs were mild ISRs and viral upper respiratory tract infections and nasopharyngitis.
[00191] The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
Claims (34)
- (1) prior treatment with at least one of PPIs, esophageal dilation, corticosteroids, allergen withdrawal, and/or diet modification;1. A method of increasing esophageal distensibility comprising:(a) selecting a patient with at least one characteristic selected from the group consisting of:(i) the patient has >15 eosinophils per high powered field (hpf) in the esophagus prior to or at the time of the treatment (“baseline”);(ii) the patient exhibits at least two episodes of dysphagia per week; and/or (iii) the patient has a Straumann Dysphagia Instrument (SDI) score >2;and (b) administering a therapeutically effective amount of a pharmaceutical composition comprising an interleukin-4/ interleukin-13 (IL-4/IL-13) pathway inhibitor to the patient in need thereof, thereby increasing esophageal distensibility, as measured by a functional lumen imaging probe.
- (2) the patient is unresponsive or resistant to prior treatment with PPIs or esophageal dilation;2. The method of claim 1, wherein the patient has moderate-to-severe eosinophilic esophagitis (EoE).
- (3) the patient has an Eosinophilic Esophagitis Severity and Activity Index (EEsAI) score >30, >40, or >50;3. The method of claim 1 or 2, wherein the patient is >18 years of age.
- (4) the patient has suffered from EoE for at least 3 years;WO 2019/028367PCT/US2018/045195 (5) the patient, prior to or at the time of administration of the IL-4/IL-13 pathway inhibitor, has or is diagnosed with a disease or disorder selected from the group consisting of food allergy, atopic dermatitis, asthma, allergic rhinitis, and/or allergic conjunctivitis; and/or (6) the patient has an elevated level of at least one biomarker selected from the group consisting of eotaxin-3, periostin, serum IgE (total and allergen-specific), IL-13, IL-5, serum thymus and activation regulated chemokine (TARC), thymic stromal lymphopoietin (TSLP), serum eosinophilic cationic protein (ECP), and/or eosinophil-derived neurotoxin (EDN).4. The method of any one of claims 1-3, wherein the patient has been treated previously with proton pump inhibitors (PPIs).
- 5. The method of any one of claims 1-4, wherein the patient has had at least one prior esophageal dilation.
- 6. The method of any one of claims 1-5, wherein the patient has at least one characteristic selected from the group consisting of:
- 7. The method of any one of claims 1-6, wherein administration of the IL-4/IL13 pathway inhibitor results in improvement of at least one parameter selected from the group consisting of:(a) reduction of at least 40% from baseline in dysphagia frequency and severity, as measured by Straumann Dysphagia Instrument (SDI) score;(b) reduction of 3 points from baseline in the SDI score;(c) reduction of more than 85% from baseline in peak intraepithelial eosinophil count in proximal, mid and/or distal regions of the esophagus;(d) increase of at least 10% from baseline in esophageal distensibility, as measured by impedance planimetry;(e) decrease of more than 50% from baseline in severity and extent of disease, as measured by EoE Histology Scoring System (HSS) score; and/or (f) reduction of more than 30% from baseline in dysphagia, as measured by Eosinophilic Esophagitis Severity and Activity Index (EEsAI) score.
- 8. The method of any one of claims 1-7, wherein the IL-4/IL-13 pathway inhibitor is administered at a dose of about 50 to about 600 mg.
- 9. The method of any one of claims 1-8, wherein the IL-4/IL-13 pathway inhibitor is administered at a dose of about 300 mg.
- 10. The method of any one of claims 1-7, wherein the IL-4/IL-13 pathway inhibitor is administered at an initial dose followed by one or more secondary doses, wherein each secondary dose is administered 1 to 4 weeks after the immediately preceding dose.WO 2019/028367PCT/US2018/045195
- 11. The method of claim 10, wherein the initial dose comprises 50 - 600mg of the IL-4/IL-13 pathway inhibitor.
- 12. The method of claim 10 or 11, wherein each secondary dose comprises 25 400mg of the IL-4/IL-13 pathway inhibitor.
- 13. The method of any one of claims 10 - 12, wherein the initial dose comprises 600mg of the IL-4/IL-13 pathway inhibitor, and each secondary dose comprises 300mg of the IL-4/IL-13 pathway inhibitor.
- 14. The method of claim 13, wherein each secondary dose is administered one week after the immediately preceding dose.
- 15. The method of claim 13, wherein each secondary dose is administered 2 weeks after the immediately preceding dose.
- 16. The method of any one of claims 2-15, wherein the administration of the IL4/IL-13 pathway inhibitor results in an improvement of at least one symptom or indication of EoE selected from the group consisting of eosinophilic inflammation of the esophagus, eosinophilic infiltration of the esophagus, thickening of the esophageal wall, food refusal, vomiting, abdominal pain, food intolerance, diarrhea, weight loss, heartbum, regurgitation, dysphagia, and/or food impaction.
- 17. The method of any one of claims 1-16, wherein the patient exhibits an allergic reaction to a food allergen contained in a food item, wherein the food item is selected from the group consisting of a dairy product, egg, wheat, soy, com, fish, shellfish, peanut, a tree nut, beef, chicken, oat, barley, pork, green beans, apple, and/or pineapple.
- 18. The method of any one of claims 1-16, wherein the patient exhibits an allergic reaction to a non-food allergen derived from dust, pollen, mold, plant, cat, dog, or insect.
- 19. The method of any one of claims 1-18, wherein the administration of the IL4/IL-13 pathway inhibitor results in reducing the level of an EoE-associated biomarker in the subject.WO 2019/028367PCT/US2018/045195
- 20. The method of claim 19, wherein the EoE-associated biomarker is selected from the group consisting of eotaxin-3, periostin, serum IgE (total and allergen-specific), IL-13, IL-5, serum TARC, TSLP, serum ECP, and/or EDN.
- 21. The method of any one of claims 1 - 20, wherein the IL-4/IL-13 pathway inhibitor is administered in combination with a second therapeutic agent or therapy, wherein the second therapeutic agent or therapy is selected from the group consisting of an IL-1 beta inhibitor, an IL-5 inhibitor, an IL-9 inhibitor, an IL-13 inhibitor, an IL-17 inhibitor, an IL-25 inhibitor, a TNFalpha inhibitor, an eotaxin-3 inhibitor, an IgE inhibitor, a prostaglandin D2 inhibitor, an immunosuppressant, a topical corticosteroid, an oral corticosteroid, a systemic corticosteroid, an inhaled corticosteroid, a glucocorticoid, a proton pump inhibitor, aNSAID, esophagus dilation, allergen removal, and/or diet management.
- 22. The method of any one of claims 1-21, wherein the IL-4/IL-13 pathway inhibitor is selected from the group consisting of an anti-IL-4 antibody, an anti-IL-13 antibody, an anti-IL-4/IL-13 bispecific antibody, an IL-4 receptor (IL-4R) inhibitor, and/or an anti-IL-4R antibody.
- 23. The method of claim 22, wherein the IL-4/IL-13 pathway inhibitor is an IL-4R inhibitor.
- 24. The method of claim 22, wherein the IL-4/IL-13 pathway inhibitor is an antiIL-4 antibody.
- 25. The method of claim 22, wherein the IL-4/IL-13 pathway inhibitor is an antiIL-13 antibody.
- 26. The method of claim 22, wherein the IL-4/IL-13 pathway inhibitor is a bispecific antibody that specifically binds to IL-4 and IL-13.
- 27. The method of any one of claims 1 - 23, wherein the IL-4/IL-13 pathway inhibitor is an antibody or antigen-binding fragment thereof that binds IL-4Ra and prevents the interaction of IL-4 and/or IL-13 with a type 1 or type 2 IL-4 receptor.
- 28. The method of claim 27, wherein the antibody or antigen-binding fragment thereof prevents the interaction of IL-4 with both type 1 and type 2 IL-4 receptors.WO 2019/028367PCT/US2018/045195
- 29. The method of claim 28, wherein the antibody or antigen-binding fragment thereof comprises the heavy chain complementarity determining regions (HCDRs) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 1 and the light chain complementarity determining regions (LCDRs) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 2.
- 30. The method of claim 29, wherein the antibody or antigen-binding fragment thereof comprises three HCDRs (HCDR1, HCDR2 and HCDR3) and three LCDRs (LCDR1, LCDR2 and LCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO: 3; the HCDR2 comprises the amino acid sequence of SEQ ID NO: 4; the HCDR3 comprises the amino acid sequence of SEQ ID NO: 5; the LCDR1 comprises the amino acid sequence of SEQ ID NO: 6; the LCDR2 comprises the amino acid sequence of SEQ ID NO: 7; and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 8.
- 31. The method of claim 30, wherein the HCVR comprises the amino acid sequence of SEQ ID NO: 1, and the LCVR comprises the amino acid sequence of SEQ ID NO: 2.
- 32. The method of any one of claims 29-31, wherein the antibody or antigenbinding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10.
- 33. The method of any one of claims 1-31, wherein the IL-4/IL-13 pathway inhibitor is dupilumab or a bioequivalent thereof.
- 34. The method of claim 23, wherein the IL-4R inhibitor is AMG317 or MEDI9314.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762541242P | 2017-08-04 | 2017-08-04 | |
US62/541,242 | 2017-08-04 | ||
US201762561593P | 2017-09-21 | 2017-09-21 | |
US62/561,593 | 2017-09-21 | ||
EP18305252.1 | 2018-03-08 | ||
EP18305252 | 2018-03-08 | ||
PCT/US2018/045195 WO2019028367A1 (en) | 2017-08-04 | 2018-08-03 | Methods for treating active eosinophilic esophagitis |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2018311981A1 true AU2018311981A1 (en) | 2020-02-20 |
Family
ID=63113646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2018311981A Pending AU2018311981A1 (en) | 2017-08-04 | 2018-08-03 | Methods for treating active eosinophilic esophagitis |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP3661551A1 (en) |
JP (2) | JP7417515B2 (en) |
KR (1) | KR20200035442A (en) |
CN (1) | CN111032084A (en) |
AU (1) | AU2018311981A1 (en) |
CA (1) | CA3071528A1 (en) |
IL (1) | IL272245A (en) |
MA (1) | MA49744A (en) |
MX (1) | MX2020001305A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117085122A (en) * | 2022-04-29 | 2023-11-21 | 中山康方生物医药有限公司 | Antibodies against human IL-4RA and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI682781B (en) * | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
CA2924873A1 (en) * | 2013-10-23 | 2015-04-30 | Genentech, Inc. | Methods of diagnosing and treating eosinophilic disorders |
EP3268032A1 (en) * | 2015-03-11 | 2018-01-17 | GlaxoSmithKline Intellectual Property Development Limited | Tslp binding proteins |
-
2018
- 2018-08-03 KR KR1020207006346A patent/KR20200035442A/en not_active Application Discontinuation
- 2018-08-03 EP EP18750578.9A patent/EP3661551A1/en active Pending
- 2018-08-03 CA CA3071528A patent/CA3071528A1/en active Pending
- 2018-08-03 MA MA049744A patent/MA49744A/en unknown
- 2018-08-03 CN CN201880050334.6A patent/CN111032084A/en active Pending
- 2018-08-03 MX MX2020001305A patent/MX2020001305A/en unknown
- 2018-08-03 JP JP2020505844A patent/JP7417515B2/en active Active
- 2018-08-03 AU AU2018311981A patent/AU2018311981A1/en active Pending
-
2020
- 2020-01-26 IL IL272245A patent/IL272245A/en unknown
-
2023
- 2023-11-13 JP JP2023192683A patent/JP2024016237A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MA49744A (en) | 2020-06-10 |
EP3661551A1 (en) | 2020-06-10 |
CN111032084A (en) | 2020-04-17 |
KR20200035442A (en) | 2020-04-03 |
IL272245A (en) | 2020-03-31 |
RU2020109331A (en) | 2021-09-06 |
JP7417515B2 (en) | 2024-01-18 |
MX2020001305A (en) | 2020-03-09 |
CA3071528A1 (en) | 2019-02-07 |
RU2020109331A3 (en) | 2021-12-28 |
JP2024016237A (en) | 2024-02-06 |
JP2020529434A (en) | 2020-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11053309B2 (en) | Methods for treating active eosinophilic esophagitis | |
US11421036B2 (en) | Methods of treating eosinophilic esophagitis by administering an antibody which inhibits interleukin-4 receptor (IL-4R) | |
US20210363264A1 (en) | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor | |
JP7434456B2 (en) | Method for treating diseases in which IL-13 activity is harmful using anti-IL-13 antibodies | |
JP2024016237A (en) | Methods for treating active eosinophilic esophagitis | |
RU2776651C2 (en) | Methods for treatment of active eosinophilic esophagitis |